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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about methyl
 
mercaptan and to emphasize the human health effects that may result from
 
exposure to it. The Environmental Protection Agency (EPA) has identified
 
1,300 sites on its National Priorities List (NPL). Methyl mercaptan has been
 
found in at least 2 of these sites. However, we do not know how many of the
 
1,300 NPL sites have been evaluated for methyl mercaptan. As EPA evaluates
 
more sites, the number of sites at which methyl mercaptan is found may change.
 
This information is important for you to know because methyl mercaptan may
 
cause harmful health effects and because these sites are potential or actual
 
sources of human exposure to methyl mercaptan.
 
When a chemical is released from a source, such as an industrial plant,
 
or from a container, such as a drum or bottle, it enters the environment as a
 
chemical emission. This emission, which is also called a release, does not
 
always lead to exposure. You can be exposed to a chemical only when you come
 
into contact with the chemical. You may be exposed to it in the environment
 
by breathing, eating, or drinking substances containing the chemical or from
 
skin contact with it.
 
If you are exposed to a hazardous chemical such as methyl mercaptan,
 
several factors will determine whether harmful health effects will occur and
 
what the type and severity of those health effects will be. These factors
 
include the dose (how much), the duration (how long), the route or pathway by
 
which you are exposed (breathing, eating, drinking, or skin contact), the
 
other chemicals to which you are exposed, and your individual characteristics
 
such as age, sex, nutritional status, family traits, life style, and state of
 
health.
 
1.1 WHAT IS METHYL MERCAPTAN?
 
Methyl mercaptan, also known as methanethiol, is a colorless gas with a
 
smell like rotten cabbage. It is a natural substance found in the blood,
 
brain, and other tissues of humans and other animals, and it is released from
 
animal feces. It occurs naturally in certain foods such as some nuts
 
(filberts) and cheese (Beaufort).
 
Methyl mercaptan is released from decaying organic matter in marshes and
 
is present in the natural gas of certain regions of the United States, in coal
 
tar, and in some crude oils. Methyl mercaptan is manufactured for use in
 
pesticides, as a jet fuel additive, in the plastics industry, and in making
 
methionine, a nutrient that is added to poultry feed. Methyl mercaptan is
 
also released as a decay product of wood in pulp mills.
 
We know very little about what happens to methyl mercaptan after it is
 
released to the environment. Because it is a gas, most of it probably goes
 
into the air. Sunlight can break it down into other substances. If methyl
 
mercaptan is released to soil, it probably then goes into the air or is
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carried through the soil by rain or any other water that contacts it. More
 
information on the properties and uses of methyl mercaptan and how it behaves
 
in the environment can be found in Chapters 3, 4 and 5.
 
1.2 HOW MIGHT I BE EXPOSED TO METHYL MERCAPTAN?
 
Methyl mercaptan is always present in your body and in your urine and
 
feces. It can also be present in the breath of persons with liver damage.
 
You can be exposed to methyl mercaptan in the air if you live near a natural
 
source of this gas, such as a marsh, an underground gas pocket, or a dump site
 
that releases it. We have no information on the levels of methyl mercaptan that
 
come from these sources.
 
Methyl mercaptan has not been found in drinking water, so you would
 
probably not be exposed to it in this way. Methyl mercaptan is a natural part
 
of certain foods, such as nuts and cheeses. It has also been approved for use
 
as a food additive. Because of its unpleasant smell, very little can be added
 
to food. You could be exposed to small amounts of methyl mercaptan by eating
 
foods that contain it. However, we have no information on the levels of
 
methyl mercaptan in food.
 
You can be exposed to methyl mercaptan if you work at a wood-pulp mill
 
or sewage treatment plant or if you work in a factory that uses it to make
 
other products such as jet fuel, pesticides, or poultry feed. Measurements of
 
methyl mercaptan in the air inside these mills were lower than 4 ppm (4 parts
 
of methyl mercaptan per million parts of air). Methyl mercaptan has been
 
found in the environmental air at 4 ppb (4 parts of methyl mercaptan per
 
billion parts of air).
 
Levels of methyl mercaptan in soil are probably very low. Even at
 
hazardous waste sites, the levels were about 83 ppb. More information on how
 
you might be exposed to methyl mercaptan is given in Chapter 5.
 
1.3 HOW CAN METHYL MERCAPTAN ENTER AND LEAVE MY BODY?
 
Methyl mercaptan can enter your body when you breathe in air or eat food
 
that contains this chemical. We do not know if methyl mercaptan can enter your
 
body through the skin or what happens to it after it enters your body. Studies
 
in rats suggested it leaves the body quickly. After methyl mercaptan reaches
 
the blood, it is either breathed out unchanged or is broken down to other
 
substances (within one hour). These substances may be breathed out from the
 
lungs or leave the body with the urine within a few hours.
 
More information on how methyl mercaptan enters and leaves the body is
 
given in Chapter 2.
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1.4 HOW CAN METHYL MERCAPTAN AFFECT MY HEALTH?
 
We have very little information on the health effects of exposure to
 
methyl mercaptan. A worker exposed to very high levels (exact amount unknown)
 
of this compound for several days when he opened and emptied tanks of methyl
 
mercaptan went into a coma (became unconscious), developed anemia (a blood
 
disorder) and internal bleeding. He died within a month after this incident.
 
We do not know whether long-term exposure of humans to low levels of
 
methyl mercaptan can result in harmful health effects such as cancer, birth
 
defects, or problems with reproduction.
 
Methyl mercaptan can be smelled and recognized in air when it is there
 
at a level of about 1.6 ppb (1.6 parts of methyl mercaptan per billion parts
 
of air). It can be smelled when it is present in water at a level far lower
 
than 1 ppb.
 
More information on the health effects of methyl mercaptan in humans and
 
animals can be found in Chapter 2.
 
1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
 
EXPOSED TO METHYL MERCAPTAN?
 
Methyl mercaptan is always present in your body. There is a test that
 
can be used to find out if it is present in your blood at levels that are
 
higher than normal, which may happen if you are exposed to high levels of this
 
substance. This test requires special equipment and is not usually available in
 
a doctor's office. It can be done in a special laboratory. However, this test
 
cannot be used to find out how much methyl mercaptan you were exposed to or to
 
predict whether harmful health effects will occur.
 
More information on how methyl mercaptan can be measured in exposed
 
humans is given in Chapters 2 and 6.
 
1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
 
PROTECT HUMAN HEALTH?
 
The federal government has set certain regulations and guidelines to
 
help protect people from the possible harmful health effects of methyl
 
mercaptan in the environment. When more than 100 pounds of methyl mercaptan
 
is released to the environment (such as during an industrial accident or
 
spill), the EPA National Response Center must be notified. The Food and Drug
 
Administration (FDA) allows methyl mercaptan to be used as a food additive but
 
does not set specific limits on the levels that can be used. The Occupational
 
Safety and Health Administration (OSHA) has set an average limit of 0.5 ppm for
 
exposure to this chemical in workplace air. The American Conference of
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Governmental Industrial Hygienists (ACGIH) has recommended that the average
 
concentration of airborne methyl mercaptan should not be more than 0.5 ppm for
 
each 8-hour exposure (time-weighted average) in a 40-hour work week.
 
More information on governmental rules for methyl mercaptan can be found
 
in Chapter 7.
 
1.7 WHERE CAN I GET MORE INFORMATION?
 
If you have any more questions or concerns not covered here, please
 
contact your state health or environmental department or:
 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology
 
1600 Clifton Road, E-29
 
Atlanta, Georgia 30333
 
This agency can also provide you with information on the location of the
 
nearest occupational and environmental health clinic. Such clinics specialize
 
in recognizing, evaluating, and treating illnesses that result from exposure to
 
hazardous substances.
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2. HEALTH EFFECTS
 
2.1 INTRODUCTION
 
The primary purpose of this chapter is to provide public health
 
officials, physicians, toxicologists, and other interested individuals and
 
groups with an overall perspective of the toxicology of methyl mercaptan and a
 
depiction of significant exposure levels associated with various adverse
 
health effects. It contains descriptions and evaluations of studies and
 
presents levels of significant exposure for methyl mercaptan based on
 
toxicological studies and epidemiological investigations.
 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
 
To help public health professionals address the needs of persons living
 
or working near hazardous waste sites, the information in this section is
 
organized first by route of exposure--inhalation, oral, and dermal--and then
 
by health effect--death, systemic, immunological, neurological, developmental,
 
reproductive, genotoxic, and carcinogenic effects. These data are discussed in
 
terms of three exposure periods--acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more).
 
Levels of significant exposure for each route and duration are presented
 
in tables and illustrated in figures. The points in the figures showing no­
observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect
 
levels (LOAELs) reflect the actual doses (levels of exposure) used in the
 
studies. LOAELs have been classified into "less serious" or "serious" effects.
 
These distinctions are intended to help the users of the document identify the
 
levels of exposure at which adverse health effects start to appear. They should
 
also help to determine whether or not the effects vary with dose and/or
 
duration, and place into perspective the possible significance of these effects
 
to human health.
 
The significance of the exposure levels shown in the tables and figures
 
may differ depending on the user's perspective. For example, physicians
 
concerned with the interpretation of clinical findings in exposed persons may
 
be interested in levels of exposure associated with "serious" effects. Public
 
health officials and project managers concerned with appropriate actions to
 
take at hazardous waste sites may want information on levels of exposure
 
associated with more subtle effects in humans or animals (LOAEL) or exposure
 
levels below which no adverse effects (NOAEL) have been observed. Estimates
 
of levels posing minimal risk to humans (Minimal Risk Levels, MRLs) may be of
 
interest to health professionals and citizens alike.
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have
 
been made, where data were believed reliable, for the most sensitive noncancer
 
effect for each exposure duration. MRLs include adjustments to reflect human
 
variability from laboratory animal data to humans.
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Although methods have been established to derive these levels (Barnes
 
et al. 1988; EPA 1989b), uncertainties are associated with these techniques.
 
Furthermore, ATSDR acknowledges additional uncertainties inherent in the
 
application of the procedures to derive less than lifetime MRLs. As an
 
example, acute inhalation MRLs may not be protective for health effects that
 
are delayed in development or are acquired following repeated acute insults,
 
such as hypersensitivity reactions, asthma, or chronic bronchitis. As these
 
kinds of health effects data become available and methods to assess levels of
 
significant human exposure improve, these MRLs will be revised.
 
2.2.1 Inhalation Exposure
 
Very little information is available on the health effects in humans or
 
experimental animals after inhalation exposure to methyl mercaptan. Most
 
studies of occupational exposure to methyl mercaptan in the pulp industry also
 
involve exposure to other sulfur-containing compounds such as hydrogen sulfide,
 
dimethyl sulfide, and sulfur dioxide as well as to methyl mercaptan (Kangas et
 
al. 1984).
 
2.2.1.1 Death
 
A single case of death resulting from occupational exposure to methyl
 
mercaptan has been located. A 53-year-old Black male laborer worked for about
 
1 week emptying tanks containing methyl mercaptan. No details of exposure
 
level were available; however, it is assumed that both inhalation and dermal
 
exposure were probably involved. The man was hospitalized in a coma,
 
developed hemolytic anemia and methemoglobinemia, and died 28 days after
 
admission (Shults et al. 1970). The immediate cause of death was determined
 
to be a massive embolus that occluded both main pulmonary arteries.
 
An LC50 of 675 ppm was reported for male and female rats exposed to 
methyl mercaptan for 4 hours (Tansy et al. 1981). However, no deaths (O/10) 
occurred in rats exposed to 400 ppm for 4 hours, and there was 100% mortality 
at 700 ppm and above. These authors also reported that no mortality was 
observed in male rats exposed to methyl mercaptan at doses up to 57 ppm for 
3 months. 
The highest NOAEL values and an LC50 for rats in each duration category 
are recorded in Table 2-l and plotted in Figure 2-1. 
2.2.1.2 Systemic Effects
 
Based on the available information, effects on body weight are the only
 
systemic effects that can be clearly associated with inhalation exposure to
 
methyl mercaptan. No studies were located regarding musculoskeletal effects in
 
humans or animals after inhalation exposure to methyl mercaptan.
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A NOAEL and a reliable LOAEL for systemic effects in rats in the
 
intermediate-duration category are recorded in Table 2-1 and plotted in
 
Figure 2-l.
 
Respiratory Effects. No studies have been located that would be useful
 
in assessing the potential effects on the respiratory system in humans
 
breathing methyl mercaptan. Irritation of mucous membranes of the nose and
 
respiratory tract have been reported by workers exposed to mercaptans in
 
general (Key et al. 1977).
 
No compound-related histopathological changes were observed in the lungs
 
of male rats exposed to methyl mercaptan at doses up to 57 ppm, 7 hours/day, 5
 
days/week, for 3 months (Tansy et al. 1981).
 
Cardiovascular Effects. Increased pulse rate and blood pressure were
 
reported by Shults et al. (1970) in a 53-year-old comatose patient who had
 
been working with tanks of methyl mercaptan. Exposure level data were not
 
available.
 
No histopathological changes were found in the hearts of male rats
 
exposed to methyl mercaptan at levels up to 57 ppm, 7 hours/day, 5 days/week,
 
for 3 months (Tansy et al. 1981).
 
Gastrointestinal Effects. No studies were located regarding
 
gastrointestinal effects in humans after inhalation exposure to methyl
 
mercaptan.
 
No evidence of histopathological changes was found in the small
 
intestines of male rats exposed to methyl mercaptan at levels up to 57 ppm,
 
7 hours/day, 5 days/week, for 3 months (Tansy et al. 1981). Intestinal
 
transit performance, as measured by the amount of small intestine traversed in
 
30 minutes, was not found to be affected by exposure in this study. There
 
was, however, a statistically significant dose-related decrease in the length
 
of the small intestines at 17 ppm and above. However, the clinical
 
significance of this observation is not clear, and it is not viewed as a
 
serious adverse effect.
 
Hematological Effects. The only information on hematologic effects
 
resulting from human inhalation and presumably dermal exposure to methyl
 
mercaptan is a case report by Shults et al. (1970). A Black 53-year-old
 
worker who had been handling and emptying tanks of methyl mercaptan for about
 
1 week became comatose and developed methemoglobinemia and hemolytic anemia
 
before his death. After transfusions, these conditions were reversed. The
 
authors postulated that the hemolysis may have been due to the oxidant effect
 
of methyl mercaptan on erythrocytes in a person who was deficient in
 
glucose-6-phosphate dehydrogenase (G-6-PD). An inherited deficiency of this
 
10
 
2. HEALTH EFFECTS
 
enzyme may be common in American Blacks (Calabrese 1986; Goldstein et al.
 
1974; Shannon and Buchanan 1982). This worker was found to have some degree
 
of G-6-PD deficiency (Shults et al. 1970).
 
No studies were located regarding hematological effects in animals after
 
inhalation exposure to methyl mercaptan.
 
Hepatic Effects. No studies were located regarding hepatic effects in
 
humans after inhalation exposure to methyl mercaptan.
 
In male rats exposed to methyl mercaptan at levels up to 57 ppm,
 
7 hours/day, 5 days/week, for 3 months, no compound-related histopathologic
 
changes of the liver were noted (Tansy et al. 1981). The authors stated that
 
results of blood chemistry studies (i.e., increased total protein with
 
decreased serum albumin) were suggestive of liver damage, but that dehydration
 
could not be ruled out as the cause.
 
Renal Effects. No studies were located regarding renal effects in
 
humans after inhalation exposure to methyl mercaptan. Shults et al. (1970)
 
reported that bilateral polycystic kidneys were found during the autopsy of a
 
53-year-old man who died after working with tanks of methyl mercaptan.
 
However, it is possible that this was a pre-existing condition.
 
No compound-related histopathologic changes in the kidneys of male rats
 
exposed to methyl mercaptan at levels up to 57 ppm, 7 hours/day, 5 days/week,
 
for 3 months (Tansy et al. 1981).
 
Dermal/Ocular Effects. Irritation of the skin and eyes have been
 
reported by workers occupationally exposed to mercaptans in general (Key
 
et al. 1977). However, there is no available information that is specifically
 
related to methyl mercaptan.
 
No studies were located regarding dermal or ocular effects in animals
 
after inhalation exposure to methyl mercaptan.
 
Other Systemic Effects. No studies were located regarding other
 
systemic effects in humans after inhalation exposure to methyl mercaptan.
 
Male rats exposed to methyl mercaptan at 57 ppm for 7 hours/day, 5 days/week,
 
for 3 months had significantly decreased body weights (Tansy et al. 1981).
 
This effect was not observed in rats exposed to 17 ppm and below. Decreased
 
levels of food consumption were not observed in rats in the 57-ppm dose group.
 
2.2.1.3 Immunological Effects
 
No studies were located regarding immunological effects in humans or
 
animals after inhalation exposure to methyl mercaptan.
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2.2.1.4 Neurological Effects
 
The only available information on neurological effects in humans exposed
 
to methyl mercaptan via inhalation is from a case study by Shults et al.
 
(1970). A 53-year-old man went into an irreversible coma after emptying tanks
 
of methyl mercaptan for about 1 week. Levels of exposure were not estimated.The
 
authors also noted minimal movement in response to painful stimuli,
 
hypoactivity of all deep tendon reflexes, and seizure activity. The patient
 
died about one month after the onset of this coma.
 
Fifteen-minute exposures to methyl mercaptan at 1,400 ppm have been
 
found to result in lethargy or coma in rats (Zieve et al. 1974). Exposures to
 
1,200 ppm and below did not result in either of these conditions. A methyl
 
mercaptan concentration of 0.5 nmol/mL in the blood was identified as the
 
level associated with coma. This study also demonstrated that the doses of
 
intraperitoneally injected ammonium acetate or sodium octanoate needed to
 
induce hepatic coma (coma following acute necrosis of the liver) were greatly
 
reduced when animals were exposed to methyl mercaptan at 1,200 ppm within
 
1 minute after injection. (However, hepatic effects were not actually
 
demonstrated in this study.) The authors suggested that methyl mercaptan
 
exposure may intensify the toxic effects of ammonia and fatty acids in human
 
hepatic failure.
 
These values are recorded in Table 2-l and plotted in Figure 2-l.
 
No studies were located regarding the following health effects in humans
 
or animals after inhalation exposure to methyl mercaptan:
 
2.2.1.5 Developmental Effects
 
2.2.1.6 Reproductive Effects
 
2.2.1.7 Genotoxic Effects
 
2.2.1.8 Cancer
 
2.2.2 Oral Exposure
 
No studies were located regarding the following health effects in humans
 
or animals after oral exposure to methyl mercaptan:
 
2.2.2.1 Death
 
2.2.2.2 Systemic Effects
 
2.2.2.3 Immunological Effects
 
2.2.2.4 Neurological Effects
 
2.2.2.5 Developmental Effects
 
2.2.2.6 Reproductive Effects
 
2.2.2.7 Genotoxic Effects
 
2.2.2.8 Cancer
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2.2.3 Dermal Exposure
 
Occupational exposure as reported in the case study by Shults et al.
 
(1970) may have involved dermal exposure since the victim's wife noted a
 
repugnant odor on his clothes; however, there is not enough information to
 
assess this possibility.
 
No studies were located regarding the following health effects in humans
 
or animals after dermal exposure to methyl mercaptan:
 
2.2.3.1 Death
 
2.2.3.2 Systemic Effects
 
2.2.3.3 Immunological Effects
 
2.2.3.4 Neurological Effects
 
2.2.3.5 Developmental Effects
 
2.2.3.6 Reproductive Effects
 
2.2.3.7 Genotoxic Effects
 
2.2.3.8 Cancer
 
2.2.4 Other Routes of Exposure
 
Because the available data on the toxicity of methyl mercaptan via
 
inhalation, oral, or dermal exposure are extremely limited, studies conducted
 
via intraperitoneal exposure have also been considered. These studies are
 
also limited in number and scope, and serve only to provide additional
 
evidence that coma is associated with exposure to this chemical.
 
2.2.4.1 Death
 
No information is available on the levels of methyl mercaptan
 
administered to animals via intraperitoneal injection that would result in
 
death. Studies described in Section 2.2.4.4 have resulted in coma in the test
 
animals; however, recovery and/or death in response to these injections were
 
not among the topics of investigation.
 
2.2.4.2 Systemic Effects
 
No studies were located regarding respiratory, cardiovascular,
 
gastrointestinal, hematological, musculoskeletal, hepatic, renal, or
 
dermal/ocular effects in humans or animals after intraperitoneal exposure to
 
methyl mercaptan.
 
2.2.4.3 Immunological Effects
 
No studies were located regarding immunological effects in humans or
 
animals after intraperitoneal exposure to methyl mercaptan.
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2.2.4.4 Neurological Effects
 
Two studies that investigated the neurological effects of
 
intraperitoneal administration of methyl mercaptan have been located. An
 
injection equivalent to 4.8 mg/kg was sufficient to induce coma in 100% of
 
treated rats in 2-4 minutes (Zieve et al. 1984). In germ-free rats
 
administered methyl mercaptan at 9.6-28.8 mg/kg, 200 nmol/mL was the minimum
 
blood concentration associated with coma (Al Mardini et al. 1984). It is
 
interesting to note that this level was much higher than the blood level of
 
0.5 nmol/mL in comatose rats reported by Zieve et al. (1974) in inhalation
 
studies.
 
In addition, an important observation was made by Al Mardini et al.
 
(1984) who reported that blood methyl mercaptan concentrations were
 
significantly higher in patients with hepatic encephalopathy (coma) than in
 
normal subjects or patients with liver disease without encephalopathy.
 
(Methyl mercaptan was not administered to any of these persons, but presumably
 
resulted from the endogenous breakdown of methionine.) Methyl mercaptan
 
concentrations were also higher (but not significantly) in the blood of liver
 
disease patients without encephalopathy than in normal subjects. These
 
findings, combined with the observations of Zieve et al. (1974) in rats with
 
liver damage from ammonium ion or octanoate (Section 2.2.1.4), suggest that
 
persons with existing liver damage may already have elevated blood levels
 
ofmethyl mercaptan and thus may be at greater risk for the neurological effects
 
of exposure to exogenous methyl mercaptan than would be persons with normal
 
livers.
 
No studies were located regarding the following health effects in humans
 
or animals after intraperitoneal exposure to methyl mercaptan:
 
2.2.4.5 Developmental Effects
 
2.2.4.6 Reproductive Effects
 
2.2.4.7 Genotoxic Effects
 
2.2.4.8 Cancer
 
2.3 TOXICOKINETICS
 
The only studies located on the toxicokinetics of methyl mercaptan have
 
been conducted via the intraperitoneal route. There is indirect evidence of
 
absorption of methyl mercaptan by humans in a human case study and by rats in
 
a toxicity study.
 
2.3.1 Absorption
 
2.3.1.1 Inhalation Exposure
 
Based on adverse effects (hemolysis, methemoglobinemia, coma, and
 
death)reported in a 53-year-old worker exposed to methyl mercaptan via
 
inhalation
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(Shults et al. 1970) and on the induction of coma in rats exposed to 1,400 ppm
 
(Zieve et al. 1974), it can be inferred that absorption occurs via this route
 
of exposure. No other data are available.
 
2.3.1.2 Oral Exposure
 
No studies were located regarding absorption in humans or animals after
 
oral exposure to methyl mercaptan.
 
2.3.1.3 Dermal Exposure
 
No studies were located regarding absorption in humans or animals after
 
dermal exposure to methyl mercaptan.
 
2.3.2 Distribution
 
No studies were located regarding distribution in humans or animals
 
after exposure to methyl mercaptan via the following routes:
 
2.3.2.1 Inhalation Exposure
 
2.3.2.2 Oral Exposure
 
2.3.2.3 Dermal Exposure
 
2.3.2.4 Other Routes of Exposure
 
After injection of 14C- or 35S-labeled methyl mercaptan into rats,
 
distribution of the radioactivity that remained in the body (from either the
 
14C or 35S label) after 6 hours was: 22.7% in plasma proteins, 17.8% in the
 
liver, 16.7% in the intestinal mucosa, 11.5% in the lungs, 11.4% in the
 
kidneys, 9.8% in the spleen, 8.5% in the testes, and 0% in the erythrocytes
 
(Canellakis and Tarver 1953). No other information on the distribution of
 
methyl mercaptan was located.
 
2.3.3 Metabolism
 
Information on the metabolism of methyl mercaptan is available only in
 
studies in rodents using intraperitoneal administration. Susman et al. (1978)
 
injected methyl mercaptan into one mouse and found the unchanged compound and
 
dimethyl sulfide in the expired breath.
 
In rats, intraperitoneal administration of methyl mercaptan resulted in
 
the excretion of CO2 and volatile sulfur-containing compounds in the expired
 
breath (Canellakis and Tarver 1953). The 35S from labeled methyl mercaptan
 
in injected rats could be found mostly (94%) as 35S04 in urine (Derr and
 
Draves 1983, 1984).
 
1
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Methyl mercaptan is an intermediate in the catabolism of the amino acid
 
methionine (Blom et al. 1988, 1989). These in vitro studies were conducted
 
with the blood of methionine-loaded patients and with human and rat
 
hepatocytes. Blom and Tangerman (1988) found that, in whole blood, methyl
 
mercaptan is oxidized by the erythrocytes, the carbon-sulfur bond is split,
 
and the resulting products are formic acid, sulfite ion, and sulfate ion.
 
2.3.4 Excretion
 
No studies were located regarding excretion by humans or animals after
 
exposure to methyl mercaptan via the following routes:
 
2.3.4.1 Inhalation Exposure
 
2.3.4.2 Oral Exposure
 
2.3.4.3 Dermal Exposure
 
2.3.4.4 Other Routes of Exposure
 
The only information available on the excretion of methyl mercaptan or 
its metabolites is found in studies in rats conducted via intraperitoneal 
administration. Within 6 hours after administration of 14C-methyl mercaptan, 
more than 40% of the administered 14C was recovered as CO2 (presumed to result 
solely from pulmonary excretion) (Canellakis and Tarver 1953). Another 6.4% was 
excreted in 1 hour in volatile sulfur compounds (route not stated), and 2.3% 
was excreted in the urine within 6 hours. Within 8 hours after 
administration of 35S-methyl mercaptan, 32% of the administered 35S was 
recovered in sulfur compounds (mostly sulfates) in the urine. Derr and Draves 
(1983), however, found that within 21 hours, 94% of the 35S-label of 35S-methyl 
mercaptan intraperitoneally administered to rats was excreted in the urine. No 
data on fecal excretion have been located. 
2.4 RELEVANCE TO PUBLIC HEALTH
 
As discussed in Section 2.2, estimates of levels of exposure to methyl
 
mercaptan posing minimal risk to humans (MRLs) were to have been made, where
 
data were believed reliable, for the most sensitive noncancer effect for each
 
route and exposure duration. However, no MRLs could be derived for methyl
 
mercaptan. Available data on effects of acute-duration inhalation exposure to
 
methyl mercaptan in humans or animals suggests that neurological effects may
 
be the most sensitive indicator of toxicity, but this information does not
 
reliably identify the threshold for this effect. Available data on effects of
 
intermediate-duration inhalation exposure to methyl mercaptan in animals does
 
not identify the most sensitive effect or the threshold for adverse effects.
 
No data were located on effects of chronic-duration inhalation exposure to
 
methyl mercaptan in humans or animals. Therefore, no inhalation MRLs were
 
derived. No data were located on effects of acute-duration, intermediate
 
duration, or chronic-duration oral exposure to methyl mercaptan in humans or
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animals, Therefore, no oral MRLs were derived. Acute-duration, intermediate
 
duration, and chronic-duration dermal MRLs were not derived for methyl
 
mercaptan due to the lack of an appropriate methodology for the development of
 
dermal MRLs.
 
The observations in a single human case study, combined with the results
 
of studies in animals, suggest that the principal health risk associated with
 
short-term exposure to high levels of methyl mercaptan is coma. Hematological
 
effects such as hemolytic anemia and methemoglobinemia may also result, but
 
there is less information on this topic. In total, the available database on
 
this chemical is so limited that the relevance of methyl mercaptan exposure to
 
public health cannot be determined.
 
Death. The accidental death of a 53-year-old worker who had been
 
handling tanks of methyl mercaptan for 1 week was reported by Shults et al.
 
(1970). After a month in a coma and despite aggressive medical intervention,
 
the patient died from a massive embolus that occluded both main pulmonary
 
arteries. The exposure level was not known or estimated. An LC50 of 675 ppm
 
was determined for a 4-hour exposure in rats (Tansy et al. 1981). However, no
 
deaths (O/10) occurred at 400 ppm. Exposure to 57 ppm for 3 months also
 
resulted in no deaths in rats. The available data indicate that high level
 
exposure to this substance, at least by inhalation, can be lethal to exposed
 
humans and animals.
 
Systemic Effects.
 
Hematological Effects. The major systemic effects reported in the case
 
study of the 53-year-old Black worker who died after acute inhalation exposure
 
to methyl mercaptan were methemoglobinemia and hemolytic anemia (Shults et al.
 
1970). The authors stated that the observed hemolysis may have been due to
 
oxidant stress to erythrocyte membranes with glucose-6-phosphate dehydrogenase
 
deficiency. In an analysis of hospital data on 14 Black children (aged 3 weeks
 
to 11 years) with hemolytic anemia, 7 of these patients were found to be
 
deficient in glucose-6-phosphate dehydrogenase in an initial screening test
 
(Shannon and Buchanan 1982). Similarly, methemoglobinemia susceptibility has
 
been attributed to this enzyme deficiency (Goldstein et al. 1974). It is
 
obviously not possible to draw firm conclusions from the single case study
 
presented by Shults et al. (1970) with no other studies in humans or animals to
 
provide evidence. However, that study does provide consistent preliminary
 
evidence for the potential for hematological effects resulting from inhalation
 
exposure to methyl mercaptan by an individual who may also be deficient in
 
erythrocytic glucose-6-phosphate dehydrogenase.
 
Other Systemic effects. The only systemic effect clearly associated with
 
methyl mercaptan in an animal study was a significant decrease in body weight
 
in rats exposed to methyl mercaptan by inhalation at 57 ppm for 3 months (Tansy
 
et al. 1981). This suggests that effects on body weight may be of concern for
 
humans exposed to methyl mercaptan.
 
 17
 
2. HEALTH EFFECTS
 
Immunological Effects. There is currently no information in humans or
 
animals to suggest that exposure to methyl mercaptan is associated with
 
immunological effects.
 
Neurological Effects. The main neurotoxic effect reported in a human
 
exposed to methyl mercaptan at high levels is coma. Shults et al. (1970)
 
reported that a 53-year-old worker who had been working with tanks of methyl
 
mercaptan for about a week went into an irreversible coma accompanied by
 
convulsions and died about 1 month later. Rats exposed via inhalation to
 
methyl mercaptan at 1,400 ppm, but not 1,200 ppm or below, for 15 minutes
 
became lethargic or comatose (Zieve et al. 1974). Intraperitoneal injections
 
of methyl mercaptan in rats can also induce coma (Al Mardini et al. 1984;
 
Zieve et al. 1984). Although this route of administration is not relevant to
 
potential human exposure to this compound, these studies serve to provide
 
additional evidence that neurological effects are a major risk when methyl
 
mercaptan is absorbed by humans.
 
Developmental Effects. There is currently no information in humans or
 
animals to suggest that exposure to methyl mercaptan is associated with
 
developmental effects, therefore the relevance to human health is not known.
 
Reproductive Effects. There is currently no information in humans or
 
animals to suggest that exposure to methyl mercaptan is associated with
 
reproductive effects, therefore the relevance to human health is not known.
 
Genotoxic Effects. There is currently no information in humans or
 
animals to suggest that exposure to methyl mercaptan is associated with
 
genotoxic effects, therefore the relevance to human health is not known.
 
Cancer. There is currently no information in humans or animals to
 
suggest that exposure to methyl mercaptan is associated with cancer effects,
 
therefore the relevance to human health is not known.
 
2.5 BIOMAREERS OF EXPOSURE AND EFFECT
 
Biomarkers are broadly defined as indicators signaling events in
 
biologic systems or samples. They have been classified as markers of
 
exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).
 
A biomarker of exposure is a xenobiotic substance or its metabolite(s)
 
or the product of an interaction between a xenobiotic agent and some target
 
molecule(s) or cell(s) that is measured within a compartment of an organism
 
(NAS/NRC 1989). The preferred biomarkers of exposure are generally the
 
substance itself or substance-specific metabolites in readily obtainable body
 
fluid(s) or excreta. However, several factors can confound the use and
 
interpretation of biomarkers of exposure. The body burden of a substance may
 
be the result of exposures from more than one source. The substance being
 
measured may be a metabolite of another xenobiotic substance (e.g., high
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urinary levels of phenol can result from exposure to several different
 
aromatic compounds). Depending on the properties of the substance (e.g.,
 
biologic half-life) and environmental conditions (e.g., duration and route of
 
exposure), the substance and all of its metabolites may have left the body by
 
the time biologic samples can be taken. It may be difficult to identify
 
individuals exposed to hazardous substances that are commonly found in body
 
tissues and fluids (e.g., essential mineral nutrients such as copper, zinc,
 
and selenium). Biomarkers of exposure to methyl mercaptan are discussed in
 
Section 2.5.1.
 
Biomarkers of effect are defined as any measurable biochemical,
 
physiologic, or other alteration within an organism that, depending on
 
magnitude, can be recognized as an established or potential health impairment
 
or disease (NAS/NRC 1989). This definition encompasses biochemical or
 
cellular signals of tissue dysfunction (e.g., increased liver enzyme activity
 
or pathologic changes in female genital epithelial cells), as well physiologic
 
signs of dysfunction such as increased blood pressure or decreased lung
 
capacity. Note that these markers are often not substance specific. They also
 
may not be directly adverse, but can indicate potential health impairment
 
(e.g., DNA adducts). Biomarkers of effects caused by methyl mercaptan are
 
discussed in Section 2.5.2.
 
A biomarker of susceptibility is an indicator of an inherent or acquired
 
limitation of an organism's ability to respond to the challenge of exposure to
 
a specific xenobiotic substance. It can be an intrinsic genetic or other
 
characteristic or a preexisting disease that results in an increase in absorbed
 
dose, biologically effective dose, or target tissue response. If
 
biomarkers of susceptibility exist, they are discussed in Section 2.7,
 
"POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."
 
2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to
 
Methyl Mercaptan
 
Methyl mercaptan itself and its metabolites, carbon dioxide and sulfate,
 
can be measured in human tissues, fluid, and excreta. However, these
 
compounds are always present in these media regardless of exposure to methyl
 
mercaptan. Elevated blood levels of methyl mercaptan may be detected in
 
persons who have recently been exposed to it, or in nonexposed persons with
 
liver disease or in hepatic coma (Al Mardini et al. 1984; Challenger and
 
Walshe 1955; Zieve 1981). In cases of liver damage, these elevated levels may
 
be the result, rather than the cause, of liver problems.
 
The best indication of exposure to methyl mercaptan would probably be a
 
combination of elevated levels of the substance itself in the breath and blood
 
along with evidence or suspicion of exposure from environmental sources. There
 
are currently no subtle or sensitive biomarkers of effects associated with
 
exposure to methyl mercaptan.
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2.5.2 Biomarkers Used to Characterize Effects Caused by Methyl Mercaptan
 
As stated previously, no subtle or sensitive biomarkers of effects
 
associated with exposure to methyl mercaptan have been identified.
 
2.6 INTERACTIONS WITH OTHER CHEMICALS
 
Interactions between mercaptans, including methyl mercaptan, and
 
Ammonium acetate or sodium octanoate in the induction of coma in rats has been
 
reported (Zieve et al. 1974). The dose of intraperitoneally injected ammonium
 
acetate required to induce coma in 50% of the rats was 1.45 mmols without
 
methyl mercaptan exposure but only 0.46 mmols when the animals were exposed to
 
methyl mercaptan via inhalation at 1,200 ppm within 1 minute after the
 
injection. Similarly, the dose of sodium octanoate decreased from 0.48 to
 
0.16 mmols to induce coma using the same procedures.
 
The condition induced in these rats was referred to as "hepatic coma"
 
(Zieve et al. 1974) because it was demonstrated in a previous study that
 
injection of an ammonium salt or fatty acid into rats resulted in coma
 
accompanied by massive hepatic necrosis. In the current study of synergism,
 
Zieve et al. (1974), hepatic damage was assumed but not demonstrated, and it
 
is not clear if methyl mercaptan exposure resulted in increased hepatic damage
 
in these rats. These results suggest, however, that human exposure to methyl
 
mercaptan in conjunction with hepatotoxins may result in exacerbated liver
 
damage and/or neurotoxicity. There is a possibility of these multiple
 
exposures in the workplace and in the vicinity of hazardous waste sites.
 
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
 
A hemolytic response to methyl mercaptan exposure, as reported in the
 
case study by Shults et al. (1970), may be enhanced by the presence of
 
inherited erythrocytic glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
 
Although hemolysis may occur in any person who is exposed to a sufficiently
 
high dose of methyl mercaptan, this enzyme deficiency may cause some persons
 
to be unusually sensitive, since it results in an inability to maintain
 
reduced glutathione which is needed for the integrity of the erythrocyte
 
membrane (Goldstein et al. 1974). The incidence of the deficiency among
 
Caucasians of European origin is relatively low, whereas there is a higher
 
incidence among certain groups of Asians and Mediterranean (Italians,
 
Sardinians, Greeks), and Middle Eastern populations (Shannon and Buchanan
 
1982). A study of hemolytic anemia in American Black children with G-6-PD
 
deficiency by Shannon and Buchanan (1982) suggests that this is another
 
population that may be susceptible to the hemolytic effects of methyl
 
mercaptan exposure. Calabrese (1986) estimated that 16% of Black males are
 
G-6-PD-deficient; Berkow et al. (1982) estimated that 10% of American Black
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males and fewer Black females have this deficiency. According to Shannon and
 
Buchanan (1982), a syndrome of acute severe hemolysis following exposure to
 
oxidative stress is associated with the Mediterranean variant of the
 
deficiency, whereas the hemolytic anemia seen in American Blacks is generally
 
mild.
 
The pattern of inheritance for G-6-PD deficiency is that of an
 
autonomous sex-linked defect (Berkow et al. 1982; Goldstein et al. 1974).
 
This is an X-linked disorder and is thus fully expressed in males who carry it
 
on their single X chromosome and in females who carry it on both X
 
chromosomes. Female heterozygotes (who have one normal and one defective gene
 
for this trait) have a wide variety of values for the enzyme which suggests
 
that other factors influence the degree to which this trait is influenced in
 
identical genotypes (Goldstein et al. 1974).
 
Studies by Zieve et al. (1974) and Al Mardini et al. (1984) suggest that
 
the major neurological effects of methyl mercaptan exposure (i.e., coma) may
 
occur at lower levels of this compound in persons with liver disease. Methyl
 
mercaptan levels may already be higher than normal in these persons and
 
additional exposure may bring their blood concentrations of this compound to a
 
more dangerous level.
 
2.8 MITIGATION OF EFFECTS
 
This section will describe clinical practice and research concerning methods
 
for reducing toxic effects of exposure to methyl mercaptan. However, because
 
some of the treatments discussed may be experimental and unproven, this
 
section should not be used as a guide for treatment of exposures to methyl
 
mercaptan. When specific exposures have occurred, poison control centers and
 
medical toxicologists should be consulted for medical advice.
 
Inhalation is the primary route of human exposure to methyl mercaptan,
 
although dermal absorption or ingestion of small amounts in food or water may
 
occur (see Chapter 5). General procedures following acute, high-level
 
exposure to methyl mercaptan consist of measures to reduce or eliminate
 
further absorption. Following inhalation exposure, these measures include
 
removal of the victim and administration of high-flow, humidified oxygen
 
(Bronstein and Currance 1988; Stutz and Janus2 1988). Following dermal and
 
ocular exposure, contaminated clothing is removed and the skin and eyes
 
thoroughly washed with water (Bronstein and Currance 1988; Stutz and Janusz
 
1988). Procedures used following acute, high-level oral exposure include
 
emptying the stomach, using care to avoid pulmonary aspiration of the gastric
 
contents, particularly in victims with severe nervous system depression or
 
seizures. Stomach emptying is followed by administration of activated
 
charcoal to bind the methyl mercaptan and a cathartic which may stimulate
 
fecal excretion (Stutz and Janusz 1988).
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Supportive measures for symptoms induced by acute, high-level exposure to
 
methyl mercaptan include administration of anticonvulsant drugs to control
 
seizures (Stutz and Janusz 1988) and blood transfusion or alkaline diuresis to
 
alleviate effects of hemolysis (Shannon and Buchanan 1982; Shults et al.
 
1970). Supportive treatment for noncardiogenic pulmonary edema, central
 
nervous system depression, and hypertension with tachycardia may be required.
 
In patients with methemoglobinemia of approximately 30% or greater methylene
 
blue is administered to reduce methemoglobin levels (Ellenhorn and Barceloux
 
1988; Goldfrank et al. 1990). However, treatment of G-6-PD deficient
 
individuals with methylene blue may be contraindicated.
 
Limited information is available regarding the retention in the body or
 
metabolism of methyl mercaptan. Studies in animals demonstrate that carbon
 
dioxide and sulfate are the final metabolites found in the expired breath
 
and/or urine and that methyl mercaptan is cleared from the body within several
 
hours (Canellkis and Traver 1953; Derr and Draves 1983, 1984; Susman et al.
 
1978). Studies with human blood indicated that methyl mercaptan is oxidized in
 
erythrocytes yielding formic acid and sulfate ion as metabolites in urine (Blom
 
et al. 1988, 1989; Blom and Tangerman 1988). No method is commonly used to
 
enhance the elimination of the absorbed dose of methyl mercaptan.
 
Acute intoxication with methyl mercaptan may cause methemoglobinemia,
 
hemolytic anemia and neurological effects leading to lethargy, seizures, coma,
 
and death (see Section 2.2). However, because of the lack of information
 
regarding the mechanism of toxicity of methyl mercaptan, no specific method for
 
reducing its toxic effects is available.
 
2.9 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
 
ATSDR (in consultation with the Administrator of EPA and agencies and programs
 
of the Public Health Service) to assess whether adequate information on the
 
health effects of methyl mercaptan is available. Where adequate information is
 
not available, ATSDR, in conjunction with the National Toxicology Program
 
(NTP), is required to assure the initiation of a program of research designed
 
to determine the health effects (and techniques for developing methods to
 
determine such health. effects) of methyl mercaptan.
 
The following categories of possible data needs have been identified by
 
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substance-specific informational needs that, if met, would reduce or eliminate
 
the uncertainties of human health assessment. In the future, the identified
 
data needs will be evaluated and prioritized, and a substance-specific research
 
agenda will be proposed.
 
22
 
2. HEALTH EFFECTS
 
2.9.1 Existing Information on Health Effects of Methyl Mercaptan
 
The existing data on health effects of inhalation, oral, and dermal
 
exposure of humans and animals to methyl mercaptan are summarized in
 
Figure 2-2. The purpose of this figure is to illustrate the existing
 
information concerning the health effects of methyl mercaptan. Each dot in
 
the figure indicates that one or more studies provide information associated
 
with that particular effect. The dot does not imply anything about the
 
quality of the study or studies. Gaps in this figure should not be
 
interpreted as "data needs" information (i.e., data gaps that must necessarily
 
be filled).
 
Figure 2-2 graphically depicts the information that currently exists on
 
the health effects that have been observed or studied in humans and animals
 
following inhalation, oral, or dermal exposure to methyl mercaptan. There is
 
little information available on this chemical, and, therefore, almost any
 
additional information would probably be useful. This section, however, will
 
attempt to focus on those areas of investigation that would appear to be the
 
most useful for a chemical about which almost nothing is known.
 
2.9.2 Data Needs
 
Acute-Duration Exposure. The available information in humans and
 
animals suggests that the nervous system is the major target organ following
 
acute inhalation exposure (Shults et al. 1970; Zieve et al. 1974). However,
 
quantitative data were available in only one study in rats (Zieve et al.
 
1974)and this was not considered sufficient to calculate an MRL via this route,
 
and no studies conducted via the oral and dermal routes were available.
 
Although any new data for this exposure duration would be useful, estimates of
 
a lethaldose via inhalation would be most helpful, because a human death has
 
been reported as a result of occupational exposure. Currently, LC,, data are
 
available only for the rat (Tansy et al. 1981). Because there are no data on
 
absorption via the oral and dermal route, it is not known if toxicity studies
 
using these routes would be useful.
 
Intermediate-Duration Exposure. There are no data on humans exposed
 
tomethyl mercaptan for this duration period. A 3-month study in rats exposed to
 
methyl mercaptan via inhalation (Tansy et al. 1981) comprises virtually the
 
entire useful database for this compound and indicates that decreased body
 
weight is the only compound-related effect that was observed. Data were not
 
considered sufficient to calculate an inhalation MEL for this exposure
 
duration due to an inadequate database. There are no animal studies using the
 
oral route, and, therefore, an intermediate oral MRL has not been calculated.
 
Any further studies using either of these routes should use doses high enough
 
to elicit clinically evident neurological effects and should focus on
 
hematological effects such as hemolytic anemia and methemoglobinemia. The use
 
of an animal model that is susceptible to these hematological effects may be
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the best choice for these tests. Dose-response information for these effects
 
would be useful in assessing the risks of persons exposed to methyl mercaptan
 
in the vicinity of hazardous waste sites and in the workplace. Studies via
 
the dermal route would also be useful if pharmacologic studies have
 
demonstrated that methyl mercaptan can be absorbed through the skin.
 
Chronic-Duration Exposure and Cancer. No chronic inhalation, oral, or
 
dermal studies in any species were located for methyl mercaptan. This appears
 
to be the most important category of duration for future study of this compound
 
because low level chronic exposure is likely to occur via the
 
inhalation route in occupational settings and in the vicinity of hazardous
 
waste sites. Although the entire population is exposed via the oral route
 
since methyl mercaptan is naturally present at low levels in certain foods,
 
this compound has not been reported in drinking water. Since the potential
 
for dermal exposure is not known, it is not clear if these studies would be
 
useful.
 
Evaluations of its carcinogenic potential via the oral and inhalation
 
routes would, therefore, also be useful. Studies using the dermal route would
 
be useful if dermal exposure were first demonstrated to occur in populations
 
living or working in the vicinity of methyl mercaptan emissions.
 
Genotoxicity. There are currently no genotoxicity data available in
 
humans or animals for methyl mercaptan. A battery of in vitro genotoxicity
 
tests would be useful as a preliminary step in determining its mutagenic
 
potential and the need for further testing.
 
Reproductive Toxicity. There are no available data on the reproductive
 
toxicity of methyl mercaptan in humans or animals via any route. Available data
 
indicate that when intraperitoneally injected into rats, some methyl mercaptan
 
is distributed to the testes (Canellakis and Tarver 1953). Based on this
 
observation, potential effects on reproductive organs and sperm count should be
 
considered in any future intermediate (go-day) or chronic durationstudies
 
conducted via any route. Studies via inhalation would probably be the most
 
relevant to assessing the potential effects on the fertility of men exposed in
 
the vicinity of hazardous waste sites or in occupational settings. This
 
information would probably also be useful in the development of MRLs for these
 
durations.
 
Developmental Toxicity. There are currently no available data on this end
 
point in humans or animals. A study in animals exposed via inhalation would be
 
useful in assessing the potential developmental effects on fetuses carried by
 
women exposed to methyl mercaptan in the vicinity of hazardous waste sites and
 
in occupational settings, since this is expected to be themain route of human
 
exposure.
 
Immunotoxicity. No studies related to the immunological effects of
 
methyl mercaptan in humans or animals have been located. Immunologic
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assessments such as effects on peripheral white blood cell counts would
 
provide useful preliminary information on this end point, especially as a part
 
of intermediate or chronic duration exposure studies using the inhalation route
 
since this is the most likely route of exposure of persons in the vicinity of
 
hazardous waste sites and in occupational settings.
 
Neurotoxicity. The available information in humans and animals
 
indicates that high level exposure to methyl mercaptan via inhalation or
 
intraperitoneal injection can result in irreversible coma (Al Mardini et al.
 
1984; Shults et al. 1970; Tansy et al. 1981; Zieve et al. 1984). Animal
 
studies that describe neurological effects and assess morphological damage to
 
the brain associated with intermediate or chronic duration inhalation exposure
 
to methyl mercaptan at levels similar to those in the vicinity of hazardous
 
waste sites or in occupational settings would be extremely useful, since
 
inhalation is expected to be the main route of human exposure in those
 
settings.
 
Epidemiological and Human Dosimetry Studies. Occupational exposure to
 
methyl mercaptan, such as occurs in pulp mills, also involves exposure to other
 
sulfur-containing compounds such as hydrogen sulfide, sulfur dioxide, and
 
dimethyl sulfide. Epidemiological studies of such populations may not provide
 
useful data since observed effects may not clearly be attributable to methyl
 
mercaptan. Human dosimetry studies would be useful, however, because
 
measurement of levels of exposure to methyl mercaptan would help to indicate
 
whether humans were at risk for methyl mercaptan-induced effects associated
 
with those levels (assuming that this toxicity information would eventually
 
become available).
 
Biomarkers of Exposure and Effect. There are no sensitive biomarkers of
 
methyl mercaptan exposure. This would be useful information, especially for the
 
levels of this compound present in the vicinity of hazardous waste sites and in
 
occupational settings. However, because methyl mercaptan is always present in
 
the human body and blood levels can become elevated as a result of liver damage
 
(without exogenous exposure), progress in this area may not be forthcoming.
 
Currently, the only effect clearly associated with methyl mercaptan
 
toxicity is coma (Shults et al. 1970). The identification of more subtle
 
effects that might result from chronic low-level exposure would be useful.
 
Absorption, Distribution, Metabolism, and Excretion. There are no
 
toxicokinetic studies for methyl mercaptan via the inhalation, oral, or dermal
 
routes. These studies would be valuable for tracing its metabolic fate
 
following each route of exposure. Studies of absorption via the oral and
 
dermal routes may be useful in helping to determine if toxicity studies using
 
these routes are warranted.
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Comparative Toxicokinetics. There is no available information on the
 
comparative toxicokinetics of methyl mercaptan. Although species differences
 
in response to methyl mercaptan exposure may exist, these studies may not be
 
useful until several other aspects of this chemical's toxicity are first
 
investigated. These comparisons would then serve as an aid in putting the
 
results of animal toxicity data into perspective in relation to its relevance
 
to potential human health effects.
 
Mitigation of effects. Recommended methods for the mitigation of acute
 
effects of methyl mercaptan poisoning include administration of oxygen if
 
exposure is by inhalation, or thorough washing of the skin and flushing the
 
eyes with water if exposure is to these organs (Bronstein and Currance 1988;
 
Stutz and Janusz 1988). Drugs may also be administered to control seizures and
 
transfusions to alleviate anemia. No information was located concerning
 
mitigation of effects of lower-level or longer-term exposure to methyl
 
mercaptan. Further information on techniques to mitigate such effects wouldbe
 
useful in determining the safety and effectiveness of possible methods for
 
treating methyl mercaptan-exposed populations surrounding hazardous waste
 
sites.
 
2.9.3 On-going Studies
 
No studies on toxicity, toxicokinetics, epidemiology, or other topics
 
discussed in Section 2.8.2, above are known to be in progress.
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3. CHEMICAL AND PHYSICAL INFORMATION
 
3.1 CHEMICAL IDENTITY
 
Common synonyms, trade names, and other pertinent identification
 
information for methyl mercaptan are listed in Table 3-1.
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
Important physical and chemical properties of methyl mercaptan are
 
listed in Table 3-2.
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4. PRODUCTION, IMPORT, USE, AND DISPOSAL
 
4.1 PRODUCTION
 
Methyl mercaptan is produced commercially by the reaction of hydrogen
 
sulfide with methanol (Santodonato et al. 1985; Windholz 1983). Methyl
 
mercaptan is manufactured by the Organic Chemical Division of Pennwalt
 
Corporation in Beaumont and Houston, Texas. Production volumes for these
 
facilities were not located (SRI 1987, 1988, 1989).
 
4.2 IMPORT/EXPORT
 
No data were located regarding the import or export of methyl mercaptan.
 
4.3 USE
 
Methyl mercaptan is used as a chemical intermediate in the production of
 
jet fuel, certain pesticides, and plastics and in the synthesis of the amino
 
acid methionine (ACGIH 1986; HSDB 1989; Santodonato et al. 1985). Methyl
 
mercaptan is also used to add odor to certain odorless hazardous gases. Methyl
 
mercaptan is not one of the chemicals considered acceptable for use as an
 
odorant in natural gas (AGA 1983; HSDB 1989; Reid 1958; Santodonato et al.
 
1985; Windholz 1983).
 
4.4 DISPOSAL
 
Since methyl mercaptan is listed as a hazardous substance, disposal of
 
wastes containing methyl mercaptan is controlled by a number of federal
 
regulations (see Chapter 7). Land disposal restrictions for methyl mercaptan
 
are among those scheduled for promulgation in 1990 (40 CPR 268.12). Methyl
 
mercaptan may be disposed of by controlled incineration, and it is a potential
 
candidate for fluidized bed and rotary.kiln incineration (HSDB 1989). No
 
quantitative data were located on the amount of methyl mercaptan disposed of in
 
waste sites.
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5. POTENTIAL FOR HUMAN EXPOSURE
 
5.1 OVERVIEW
 
Methyl mercaptan is a naturally occurring gaseous compound produced as a
 
result of microbial degradation and present in trace amounts in natural gas.
 
It is likely to volatilize from soil and water and be photooxidized in the
 
atmosphere. Methyl mercaptan is probably mobile in soils, and it is not
 
likely to bioaccumulate.
 
Human exposure to trace amounts of methyl mercaptan probably occurs from
 
all environmental media. However, since this compound has an extremely
 
unpleasant odor and the odor threshold is quite low, it is unlikely that
 
significant human exposure to methyl mercaptan will occur, except possibly in
 
the vicinity of sewage treatment plants or industrial facilities or in the
 
workplace.
 
The EPA has identified 1,177 NPL sites. Methyl mercaptan has been
 
found at 2 of the sites evaluated for the presence of this chemical. However,
 
we do not know how many of the 1,177 NPL sites have been evaluated for this
 
chemical. As more sites are evaluated by the EPA, the number may change (View
 
1989). The frequency of occurrence at these sites within the United States
 
can be seen in Figure 5-l.
 
5.2 RELEASES TO THE ENVIRONMENT
 
Releases of methyl mercaptan may occur from industrial sources.
 
However, manufacturers, users, and processors of methyl mercaptan are not
 
required to report quantities of this substance released to environmental
 
media, since methyl mercaptan is not on the SARA Section 313 Toxic Chemical
 
List. Therefore, releases of methyl mercaptan during normal operations are
 
not reported in the Toxics Release Inventory (TRI 1989).
 
5.2.1 Air
 
Methyl mercaptan is released to the atmosphere from both natural and 
anthropogenic sources. Natural sources-include vegetation, animal wastes, 
microbial degradation, and natural gas (Adams et al. 1979; Farwell et al. 
1979; Graedel 1978; Reid 1958). Estimation of average methyl mercaptan 
emission from a saline marsh in North Carolina was 6.56 g sulfur/m2/year 
(Adams et al. 1979). No other quantitative data regarding emissions from 
natural sources were located. 
Potential industrial emission sources include wood pulp, oil shale, and
 
petroleum-processing plants and sewage treatment plants (EPA 1987b; Graedel
 
1978; Reid 1958; Sklarew et al. 1984). Releases may also occur from .
 
hydrolysis or combustion of wool (Junk and Ford 1980; Reid 1958). A survey of
 
about 2,950 industrial facilities in North Carolina reported fugitive and
 
stack emissions of methyl mercaptan totalling 239,594 pounds/year (McCune
 
1990).
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5.2.2 Water
 
No data were located regarding the amount of methyl mercaptan released
 
to water. However, this compound was identified in both the influent and the
 
effluent of a wastewater treatment plant. It is likely that methyl mercaptan
 
is formed in the water by chemical reaction or microbiological fermentation,
 
rather than being released from industrial or municipal sources (Reid 1958;
 
Van Langenhove et al. 1985). Data from the Contract Laboratory Program (CLP)
 
Statistical Database indicate that methyl mercaptan was not detected in
 
surface water or groundwater at about 400 hazardous waste sites (CLPSD 1986).
 
5.2.3 Soil
 
Methyl mercaptan occurs naturally in many soils and may be adsorbed to
 
the soil from the atmosphere (Smith et al. 1973). No data were located
 
regarding land releases of methyl mercaptan from industrial sources. Land
 
disposal.restrictions have been proposed for methyl mercaptan (EPA 1989c).
 
Methyl mercaptan was detected in two soil samples at a geometric mean 
concentration in positive samples of 83 µg/kg, at 1 of 455 hazardous waste 
sites (CLPSD 1986). It is important to note that the CLP Statistical Database 
includes data from both NPL and non-NPL sites. Since methyl mercaptan may 
occur naturally in soils, occurrence at a hazardous waste site does not 
necessarily indicate a release to the environment from the site. 
5.3 ENVIRONMENTAL FATE
 
5.3.1 Transport and Partitioning
 
Methyl mercaptan is a gas with a vapor pressure of 1.97 atm at 25°C (EPA 
1983). A small fraction of atmospheric methyl mercaptan may dissolve intowater 
vapor (such as clouds and rain drops). A Henry's law constant (H) 
estimates the tendency of a chemical to partition between its gas phase and 
water. A value for H has not been experimentally measured, but it may be 
estimated by dividing the vapor pressure of methyl mercaptan by its water 
solubility at the same temperature (Mabey et al. 1982). In this case, an 
estimated value for H is 3.85x10-3 atm-m3/mole (EPA 1983). The magnitude of 
this value suggests that only a small fraction of gaseous methyl mercaptan 
would dissolve in water and that most would remain in the air. 
Gaseous methyl mercaptan may also partition to soils. Sorption 
capacities of six-air-dry soil samples ranged from 2.4 to 32.1 mg CH3,SH per g 
of soil (Smith et al. 1973). The range for most soils was 2.2-21.4 mg/g of 
soil. These authors concluded that soil may be a sink for gaseous 
organosulfur compounds. No information was located on the fate of sorbed 
methyl mercaptan. 
36
 
5. POTENTIAL FOR HUMAN EXPOSURE
 
Methyl mercaptan is very soluble in water. Its solubility at 20°C is
 
approximately 23.3 g/L (EPA 1983). The magnitude of the estimated Henry's law
 
constant (3.85x10-3atm-m3/mole) indicates that a large fraction of the
 
dissolved methyl mercaptan will volatilize from solution, depending on
 
temperature, relative humidity, air currents, and the extent of mixing of the
 
solution.
 
Methyl mercaptan may not be bioconcentrated significantly in water; 
however, no information was located on this topic. An octanol/water partition 
coefficient (Kow) estimates the partitioning of a chemical between octanol and 
water. Octanol is believed to best imitate the fatty structures in plants and 
living animal tissues. Based on its solubility in water (Hassett et al. 
1983), the Kow of methyl mercaptan can be calculated as approximately 19. 
This low value suggests that methyl mercaptan will not partition to fat 
tissues significantly. A bioconcentration factor (BCF) relates the 
concentration of chemical in aquatic plants or animals to the concentration of 
the chemical in the medium in which they live. Based on the empirical 
regressions of Kenaga (1980) using soil sorption parameters, an estimated BCF 
for methyl mercaptan is about l-2. This low BCF indicates that 
bioconcentration is not a significant fate mechanism for volatile methyl 
mercaptan released into the environment. However, no experimentally-measured 
BCFs for methyl mercaptan were located to corroborate these predicted values. 
Methyl mercaptan in water may have very little tendency to be adsorbed
 
by soils and sediments. The extent of adsorption of sparingly water-soluble
 
compounds is often highly correlated with the organic-carbon content of the
 
adsorbent (Hassett et al. 1983). When adsorption is expressed as a function
 
of organic-carbon content, an organic carbon/water partition coefficient (Koc) 
is generated, and may be used to rank the relative mobility of the chemical in 
soil-water systems. Based on its solubility in water, an estimated Koc for 
methyl mercaptan can be calculated as 17, using the empirical regression of 
Hassett et al. (1983). This low value indicates that methyl mercaptan is very 
highly mobile in soil as compared with other compounds listed by Roy and 
Griffin (1985). However, methyl mercaptan is not a sparingly soluble chemical 
in water. Methyl mercaptan is also a weak acid that dissociates in water, 
yielding an anion. The adsorption of ionic chemicals cannot be predicted by 
Koc concepts. The dissociation constants (pKa) of mercaptans in general are 
on the order of 11.4 (Reid 1958; Yabroff 1940). Consequently, the relative 
proportion of methyl mercaptan as an ion is probably insignificant in 
environmentally-relevant waters where the pH is less than 9. Therefore, the 
estimated Koc value of 17 may be a reasonable indicator of how this chemical 
partitions between water and soil. No corroborative information was located. 
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5.3.2 Transformation and Degradation
 
5.3.2.1 Air
 
The major fate of atmospheric methyl mercaptan is photooxidation. 
Methyl mercaptan may be transformed by photon-photolytic oxidation, yielding 
hydrogen, sulfur dioxide, dimethyl disulfide, and other polysulfides (Haines 
et al. 1956; Sheraton and Murray 1981). Methyl mercaptan may also be oxidized 
by tropospheric oxygen radicals, yielding dimethyl disulfide and other sulfide 
compounds (Nip et al. 1981). The rate constant for this reaction at ambient 
temperatures (about 25°C) has been measured to be approximately 1.77-1.90x10-12 
cm 3/molecule-set (Nip et al. 1981; Slagle et al. 1976). If the mean 
concentration of ground-state oxygen radicals is about 5x10-4 molecules/cm3 
(Cupitt 1980), then the atmospheric half-life of methyl mercaptan is on the 
order of 4 months. 
Methyl mercaptan may be more rapidly transformed by interacting with 
atmospheric hydroxyl radicals. The measured rate constant for this reaction 
at ambient temperatures ranges from 2.1 to 9.04x10-11 cm3/molecule-see 
(Atkinson et al. 1977; Cox and Sheppard 1980; Hynes and Wine 1987; Mac Leod 
et al. 1984; Wine et al. 1984). Given that the concentration of tropospheric 
hydroxyl radicals varies from 3x105 to about 1x107 molecules/cm3 (Mac Leod et 
al. 1984), it follows that the atmospheric half-life of methyl mercaptan is on 
the order of 0.2-30 hours. Consequently, it appears that gaseous methyl 
mercaptan is labile in the troposphere. Transformation products include 
sulfur dioxide, methylsulfenic acid (CH3SOH), and methyl sulfide radicals 
(Hatakeyama and Akimoto 1983). Several other reaction products have been 
predicted but not confirmed. 
Experimental data have also demonstrated that methyl mercaptan is labile
 
in polluted air where nitrogen oxide (NO
x
) concentrations are higher (Balla and
 
Heicklen 1985; Sickles and Wright 1979). Nitrogen oxides catalyze the
 
photooxidative transformations of methyl mercaptan. Reaction products
 
underthese conditions include sulfur dioxide, nitric acid, formaldehyde,
 
methylnitrate, methanesulfonic acid, inorganic sulfate (Grosjean 1984),
 
dimethyldisulfide, and nitric oxide (Balla and Heicklen 1985).
 
Reaction with the nitrate radical (NO3) may be the dominant atmospheric 
loss process for methyl mercaptan under certain conditions (Dlugokencky and 
Howard 1988; Mac Leod et al. 1986). The rate constant for the reaction of 
atmospheric methyl mercaptan with NO3 was recently determined (Dlugokencky and 
Howard 1988; Mac Leod et al. 1986). Based on a rate constant of about 
1x1O-l2 cm3/molecule-set and a NO3 concentration of 2.4x108 molecule/cm
3
, 
Mac Leod et al. (1986) calculated an atmospheric lifetime of 1.2 hours for 
methyl mercaptan, less than the estimated atmospheric lifetime (8.4 hours) 
based on reaction with the OH radical. 
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5.3.2.2 Water
 
Very little is known about nonbiologically-mediated transformations of
 
methyl mercaptan in water. It seems likely that methyl mercaptan will
 
photooxidize and oxidize in water, but no information was located.
 
5.3.2.3 soil
 
Methyl mercaptan may be degraded by methanogenic bacteria in soil, but
 
there is little information available. Methyl mercaptan in solution was
 
metabolized to methane and carbon dioxide when in contact with anaerobic
 
freshwater sediments and sewage sludge (Zinder and Brock 1978). No other
 
information on transformation or degradation in soil was located.
 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
 
5.4.1 Air
 
Methyl mercaptan was detected in ambient air at 4 ppb (8.2 µg/m3> and in 
a primary school in Japan at 2.8 ppb (5.7 µg/m3) (Okita 1970). No other 
studies were located regarding atmospheric concentrations of methyl mercaptan. 
5.4.2 Water
 
Groundwater and surface water monitoring studies do not generally
 
include methyl mercaptan. This compound was not detected in a screen of about
 
1,800 community and private wells in Wisconsin (Krill and Sonzogni 1986). No
 
other studies regarding water concentrations of methyl mercaptan were located.
 
5.4.3 Soil
 
Although methyl mercaptan is produced by microbial degradation in soils,
 
is adsorbed from the atmosphere by soil, and is volatilized from soil (Adams et
 
al. 1 979; Farwell et al. 1979; Reid 1958; Smith et al. 1973), no
 
quantitative data on the concentration of methyl mercaptan in ambient soils
 
were located.
 
5.4.4 Other Environmental Media
 
Methyl mercaptan has been identified as a volatile component of roasted
 
filberts and Beaufort cheese (Dumont and Adda 1978; Kinlin et al. 1972).
 
Trace amounts are present in the roots and leaves of some plants, in natural
 
gas and, as a result of digestive and metabolic processes, in urine and feces
 
(Reid 1958). Methyl mercaptan is also found in commercially extractable
 
quantities in the "sour gas" of west Texas (Reid 1958).
 
39
 
5. POTENTIAL FOR HUMAN EXPOSURE
 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
 
Since methyl mercaptan is a naturally occurring substance present in
 
foods and sometimes formed during digestive and metabolic processes, the
 
general population will most likely be exposed to trace amounts of this
 
compound. However, the available data are inadequate to estimate the extent
 
of exposure of the general population to either natural or anthropogenic
 
sources of methyl mercaptan.
 
Inhalation exposure in occupational settings is probably the most
 
significant human exposure scenario for methyl mercaptan. Santodonato et al.
 
(1985) estimated that about 19,000 workers were potentially exposed to methyl
 
mercaptan in the 1970s. The estimate of workers potentially exposed to methyl
 
mercaptan increased from 357 in the early 1970s to about 6,200 in the early
 
1980s (NOES 1989; NOHS 1989). Neither the NOHS nor the NOES databases contain
 
information on the frequency, concentration, or duration of exposure of
 
workers to any of the chemicals listed therein. These surveys provide only
 
estimates of the number of workers potentially exposed to chemicals in the
 
workplace. Most occupational exposures are likely to occur in sewage
 
treatment plants and pulp mills, rather than in methyl mercaptan production or
 
consumptive use facilities. Mean methyl mercaptan concentrations in workplace
 
air ranged from 0.070 to 0.263 ppm in sewage plants and from 0.021 to 3.70 ppm
 
in pulp mills in Finland (Kangas and Ryosa 1988; Kangas et al. 1984) and from
 
0.55 to 1.06 ppm at a lockgate on a Japanese river (Okita 1970). No other data
 
on workplace air concentrations were located.
 
Since methyl mercaptan has a penetrating and extremely unpleasant odor
 
and the odor threshold in air is quite low (1.6 ppb) (Amoore and Hautala
 
1983), it is unlikely that humans would willingly tolerate exposure to
 
concentrations much above the odor threshold for any substantial time period.
 
However, humans in occupational settings may rapidly succumb to extremely high
 
levels of methyl mercaptan, as in the case of the worker who died after
 
emptying tanks of methyl mercaptan (see Chapter 2).
 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
 
Workers in sewage treatment plants, pulp mills, chemical plants, and
 
other industrial or agricultural settings where chemical or microbiological
 
formation of methyl mercaptan is significant would have potentially high
 
exposure to this compound. People living in the immediate vicinity of these
 
facilities as well as in the vicinity of hazardous waste sites also have
 
higher exposure potential than does the general population.
 
5.7 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
 
ATSDR (in consultation with the Administrator of EPA and agencies and programs
 
of the Public Health Service) to assess whether adequate information on the
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health effects of methyl mercaptan is available. Where adequate information
 
is not available, ATSDR, in conjunction with the NTP, is required to assure
 
the initiation of a program of research designed to determine the health
 
effects (and techniques for developing methods to determine such health
 
effects) of methyl mercaptan.
 
The following categories of possible data needs have been identified by
 
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substance-specific informational needs that, if met, would reduce or eliminate
 
the uncertainties of human health assessment. In the future, the identified
 
data needs will be evaluated and prioritized, and a substance-specific research
 
agenda will be proposed.
 
5.7.1 Data Needs
 
Physical and Chemical Properties. The dissociation constant of methyl
 
mercaptan in water is not known precisely (Reid et al. 1958; Yabroff 1940) and
 
this measurement would be useful in predicting the environmental fate and
 
transport of this compound. A laboratory verification of the estimated
 
Henry's law constant for methyl mercaptan (Hassett et al. 1983) would provide
 
a more accurate measurement of air-water partitioning.
 
Production, Import/Export, Use, and Disposal. No data were located with
 
regard to past or present production, use, release, or disposal of methyl
 
mercaptan. Since most human exposure to methyl mercaptan is not associated with
 
production, use, or disposal, but rather with sewage treatment, wood pulping,
 
or oil processing facilities (EPA 1987b; Graedel 1978; Reid 1958; Sklarew et
 
al. 1984), additional data on its production and use will probably not
 
significantly affect estimates of human exposure to this compound. However,
 
data on methyl mercaptan releases from those facilities where the chemical is
 
produced inadvertently (sewage treatment, wood pulping, etc.) would be useful
 
in evaluating the potential for human exposures.
 
Environmental Fate. Small amounts of methyl mercaptan may partition
 
from air to water or soil (EPA 1983; Smith et al. 1973). Based on measured
 
physical properties, methyl mercaptan is likely to volatilize from water to
 
air (EPA 1983), but has little tendency to adsorb to soils (Hassett et al.
 
1983). Methyl mercaptan is likely to be mobile in environmental media
 
(Hassett et al. 1983). Additional research on the soil sorption of gaseous
 
methyl mercaptan may be helpful in describing the transport of the gas phase
 
in the vadose zone. The reaction mechanisms of methyl mercaptan
 
transformations in the atmosphere are fairly-well understood (Atkinson et al.
 
1977; Balla and Heickler 1985; Cox and Sheppard 1980; Dlugokencky and Howard
 
1988; Haines et al. 1956; Hynes and Wine 1987; Mac Leod et al. 1986; Nip
 
et al. 1981; Sheraton and Murray 1981; Slagle et al. 1976), but the
 
environmental fates of some of the transformation products are not well known.
 
Very little is known about the fate of methyl mercaptan in water. It would be
 
helpful to collect data on oxidation, hydrolysis, photodegradation, and
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biodegradation in surface water and groundwater. Research on the
 
biodegradation and abiotic transformation of methyl mercaptan in soils would
 
also be useful.
 
Bioavailability from Environmental Media. Methyl mercaptan is soluble in
 
water and may have very little tendency to be adsorbed to soils or
 
sediments (EPA 1983; Hassett et al. 1983). Therefore, it will be bioavailable
 
from natural waters. However, there are no data on the potential absorption
 
of methyl mercaptan via the oral or dermal routes. These data would be useful
 
in assessing the potential effects of recreational use of natural waters
 
contaminated with methyl mercaptan. Information on the absorption of inhaled
 
methyl mercaptan released to air would also be useful in assessing its
 
bioavailability from that medium.
 
Food Chain Bioaccumulation. There are no data on the bioconcentration of
 
methyl mercaptan by aquatic organisms, or data on the bioaccumulation of methyl
 
mercaptan in the food chain. However, this lack of data may not be amajor
 
limitation, because the food chain bioaccumulation of methyl mercaptan is
 
unlikely owing to its high volatility and water solubility (EPA 1983; Hassett
 
et al. 1983).
 
Exposure Levels in Environmental Media. There are few studies measuring
 
concentrations of methyl mercaptan in any environmental media (Krill
 
andSonzogni 1986; Okitu 1970). Since levels in ambient air, water, and soil are
 
unknown, monitoring studies would confirm the presence or absence of this
 
compound in these media. Data on ambient air levels at hazardous waste sitesand
 
estimates of human intake would be particularly useful.
 
Exposure Levels in Humans. Exposures of humans to natural sources of
 
methyl mercaptan are difficult to estimate. Measurements of methyl mercaptan
 
in workplace air would be useful in estimating occupational exposures.
 
Because methyl mercaptan is always present in human tissue independent of
 
exposure, these levels cannot be used as a measure or indication of exposure
 
without confirmatory data on exogenous levels of methyl mercaptan.
 
Exposure Registries. No exposure registries for methyl mercaptan were
 
located. This compound is not currently one of the compounds for which a
 
subregistry has been established in the National Exposure Registry. The
 
compound will be considered in the future when chemical selection is made for
 
subregistries to be established. The information that is amassed in the
 
National Exposure Registry facilitates the epidemiological research needed to
 
assess adverse health outcomes that may be related to the exposure to this
 
compound.
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5.7.2 On-going Studies
 
Remedial investigations and feasibility studies conducted at the 2 NPL
 
sites known to be contaminated with methyl mercaptan will add more information
 
to the available database on exposure levels in environmental media and
 
exposure levels in humans. No other information was located on any on-going
 
studies on the fate, transport, or potential for human exposure to methyl
 
mercaptan.
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The purpose of this chapter is to describe the analytical methods that
 
are available for detecting and/or measuring and monitoring methyl mercaptan
 
in'environmental media and in biological samples. The intent is not to
 
provide an exhaustive list of analytical methods that could be used to detect
 
and quantify methyl mercaptan. Rather, the intention is to identify
 
well established methods that are used as the standard methods of analysis. Many
 
of the analytical methods used to detect methyl mercaptan in
 
environmental samples are the methods approved by federal agencies such as EPA
 
and the National Institute for Occupational Safety and Health (NIOSH). Other
 
methods presented in this chapter are those that are approved by groups such as
 
the Association of Official Analytical Chemists (AOAC) and the American Public
 
Health Association (APHA). Additionally, analytical methods are included that
 
refine previously used methods to obtain lower detection limits, and/or to
 
improve accuracy and precision.
 
As a volatile material boiling at only 5.95°C (Windholz 1983), methyl 
mercaptan, CH3SH, also called methanethiol, is readily determined by gas 
chromatographic analysis. The sensitivity and selectivity of detection are 
increased by the use of sulfur-selective detectors; in one study, substitution 
of a sulfur-selective flame photometric detector for a flame ionization 
detector reduced the detection limit from 20 to 2 µg/unit sample (Knarr 
andRappaport 1980). Hydrogen sulfide (H2S), dimethyl sulfide ([CH3]2S), and 
dimethyl disulfide ([CH3]2S2) are other reduced sulfur compounds that may occur 
along with methyl mercaptan and are commonly determined along with it. 
Normally, methyl mercaptan is collected from the gas phase or from vapor 
evolved from the sample matrix on a column of solid sorbent, such as Tenax@. 
Collection on molecular sieve is also possible (Kangas and Ryosa 1988), 
although problems are encountered from incomplete desorption of methyl 
mercaptan from molecular sieve. Cryogenic (low temperature) collection may also 
be possible and is less likely to lead to alterations of the analyte in the 
collection apparatus (Brettell and Grob 1985). The presence of water can result 
in reduced sorption capacity for methyl mercaptan as well as decomposition 
during thermal desorption. Sorption efficiency is improved markedly by removal 
of water from the air stream with calcium chloride (Tangerman 1986). Purge-
and-trap techniques are used to collect methyl mercaptan from water (Badings et 
al. 1985). Headspace vapor in equilibrium with the sample in a closed container 
may also be subjected to gas chromatography. 
6.1 BIOLOGICAL MATERIALS
 
Methods for detection of methyl mercaptan in biological materials are
 
summarized in Table 6-l.
 
Methyl mercaptan has been determined in a variety of biological
 
materials as shown in Table 6-l. Normally,'for determination in biological
 
samples, methyl mercaptan is released from the sample matrix and collected on
 
a column of solid sorbent, cryogenically or as headspace gas. As a result of
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Phase II metabolic reactions in biological systems (Manahan 1989), methyl
 
mercaptan may be bound as conjugates from which it must be released prior to
 
analysis. Two such bound fractions of methyl mercaptan have been identified
 
in human serum (Tangerman et al. 1985). In one fraction, from which the
 
methyl mercaptan is released by acid, the methyl mercaptan is thought to be
 
bound as methyl-beta-D-thioglucuronide. In another fraction methyl mercaptan
 
is covalently bound to proteins in a disulfide linkage and is released by
 
reaction with dithiothreitol.
 
6.2 ENVIRONMENTAL SAMPLES
 
For the determination of methyl mercaptan in air, the analyte is usually 
trapped and concentrated from a large volume of air on a solid sorbent such as 
Tenax, activated carbon, or molecular sieve from which it is released 
thermally for subsequent measurement. It is advisable to dry the air sample 
with calcium chloride prior to collection of methyl mercaptan to preventanalyte 
decomposition on the collection medium (Kangas and Ryosa 1988; 
Tangerman 1986). For aqueous and solid waste samples, methyl mercaptan is 
purged with an inert gas and collected on a solid such as Tenax, or 
cryogenically, followed by thermal desorption and measurement. Gas 
chromatography using sensitive and highly specific mass spectrometry (MS) or 
highly sensitive flame photometric detection (FPD) for detection is the 
analytical method of choice for the determination of methyl mercaptan in 
environmental samples. 
Methods for the determination of methyl mercaptan in environmental
 
samples are summarized in Table 6-2.
 
6.3 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
 
ATSDR (in consultation with the Administrator of EPA and agencies and programs
 
of the Public Health Service) to assess whether adequate information on the
 
health effects of methyl mercaptan is available. Where adequate informationis
 
not available, ATSDR, in conjunction with the NTP, is required to assurethe
 
initiation of a program of research designed to determine the health effects
 
(and techniques for developing methods to determine such health effects) of
 
methyl mercaptan.
 
The following categories of possible data needs have been identified by
 
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substance-specific informational needs that, if met, would reduce or eliminate
 
the uncertainties of human health assessment. In the future, the identified
 
data needs will be evaluated and prioritized, and a substance-specific ­
research agenda will be proposed.
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6.3.1 Data Needs
 
Methods for Determining Biomarkers of Exposure and Effect. Sensitive
 
and selective methods are available for the qualitative and quantitative
 
measurement of methyl mercaptan in biological materials, after it is separated
 
from its sample matrix (Al Mardini et al. 1984; Hayward et al. 1977; Johnsonand
 
Tonzetich 1985; Rimbault et al. 1986; Tangerman et al. 1983, 1985). However,
 
there are currently no methods available to qualitatively or
 
quantitatively correlate exposure to methyl mercaptan with biomarkers in
 
tissue or fluid. As discussed previously (Section 2.5), tissue and fluid
 
levels of methyl mercaptan can be independent of exogenous exposure to that
 
compound.
 
In the analysis of methyl mercaptan in biological materials, capillary
 
gas chromatography, also commonly known as high-resolution gas chromatography
 
(HRGC), has greatly facilitated the analysis of compounds such as methyl
 
mercaptan that can be measured by gas chromatography and has resulted in vast
 
improvements in resolution and sensitivity. The instrumental capability to
 
separate volatile analytes by HRGC is, for the most part, no longer the
 
limiting factor in their analysis.
 
It would be useful to have the means to transfer analytes that have been
 
isolated from a biological matrix, quantitatively and in a narrow band, to the
 
HRGC, and to identify and accurately measure the quantity of compounds in the
 
HRGC peaks. Mass spectrometric detection and Fourier transform infrared
 
spectroscopy (FTIR) may prove to be the most useful methods for these
 
functions.
 
There is a lack of standard methods for the measurement of metabolites of
 
methyl mercaptan in biological materials and development of these methods would
 
facilitate their determination in routine practice.
 
Specific methods for biomarkers that correlate levels of methyl
 
mercaptan or its metabolites with toxic effects in exposed populations are not
 
available. These methods would be helpful in defining the potential health
 
risks of certain tissue or fluid levels of these compounds, independent of
 
their source.
 
Methods for Determining Parent Compounds and Degradation Products in
 
Environmental Media. Methods for determining the parent compound, methyl
 
mercaptan, in water, air and waste samples with excellent selectivity and
 
sensitivity are well developed (ASTM 1987, 1988; Badings et al. 1985; De Souza
 
1987; EPA 1986; Kang as and Ryosa 1988; Knarr and Rappaport 1980; Tangerman
 
1986; Van Langenhove et al. 1985), so the database in this area is good
 
andundergoing constant improvement. For example, research is on-going to
 
develop a "Master Analytical Scheme" for organic compounds in water (Michael et
 
al. 1988), which includes methyl mercaptan as an analyte. The overall goal is
 
to detect and quantitatively measure organic compounds at 0.1 µg/L in drinking 
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water, 1 ug/L in surface waters, and 10 µg/L in effluent waters. Analytes are 
to include numerous nonvolatile compounds and some compounds that are only 
"semi-soluble" in water, as well as volatile compounds (bp<l50"C). 
Improved methods are needed for the determination of methyl mercaptan in
 
solid environmental samples, including soil and sediments. The standard EPA
 
Method 8240 for gas chromatography/mass spectrometry of volatile organics in
 
wastes, soils, and sediments (EPA 1986) could be tested thoroughly for methyl
 
mercaptan analysis and optimized for this application.
 
Sampling methodologies for compounds such as methyl mercaptan continue
 
to pose problems such as nonrepresentative samples, insufficient sample
 
volumes, contamination, and labor-intensive, tedious extraction and
 
purification procedures (Green and Le Pape 1987). It is desirable to have
 
means to measure organic compounds such as methyl mercaptan in situ in water
 
and other environmental media without the need for sampling and extraction
 
procedures to isolate the analyte prior to analysis.
 
Degradation products of methyl mercaptan in environmental media are
 
difficult to determine because these products may come from a number of
 
sources other than methyl mercaptan.
 
6.3.2 On-going Studies
 
The Environmental Health Laboratory Sciences Division of the Center for
 
Environmental Health and Injury Control, Centers for Disease Control, is
 
developing methods for the analysis of methyl mercaptan and other volatile
 
organic compounds in blood. These methods use high resolution gas
 
chromatography and magnetic sector mass spectrometry which gives detection
 
limits in the low parts per trillion range.
 
Examination of the literature suggests that other studies are underway
 
to improve means for determining methyl mercaptan and other reduced sulfur
 
compounds in biological samples and environmental media. Improvements
 
continue to be made in chromatographic separation and detection, including
 
supercritical fluid extraction and supercritical fluid chromatography (Smith
 
1988). Fourier transform infrared flow cell detectors are sensitive and
 
selective for the detection of compounds such as methyl mercaptan that have
 
been separated by fluid chromatography (Wieboldt et al. 1988). Immunoassay
 
methods of analysis are very promising for the determination of various
 
organic pollutants and toxicants, and it is reasonable to assume that methyl
 
mercaptan, and particularly its metabolites such as methyl-beta-

Dthioglucuronide are candidates for this type of analysis.
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7. REGULATIONS AND ADVISORIES
 
Because of its potential to cause adverse health effects in exposed
 
people, a number of regulations and guidelines have been established for
 
methyl mercaptan by various national and state agencies. These values are
 
summarized in Table 7-1.
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9. GLOSSARY
 
Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, as
 
specified in the Toxicological Profiles.
 
Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical adsorbed 
per unit weight of organic carbon in the soil or sediment to the concentration 
of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or 
soil (i.e., the solid phase) divided by the amount of chemical in the solution 
phase, which is in equilibrium with the solid phase, at a fixed solid/solution 
ratio. It is generally expressed in micrograms of chemical sorbed per gram of 
soil or sediment. 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
 
chemical in aquatic organisms at a specific time or during a discrete time
 
period of exposure divided by the concentration in the surrounding water at
 
the same time or during the same period.
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group
 
of studies, that produces significant increases in the incidence of cancer (or
 
tumors) between the exposed population and its appropriate control.
 
Carcinogen -- A chemical capable of inducing cancer.
 
Ceiling Value -- A concentration of a substance that should not be exceeded,
 
even instantaneously.
 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified
 
in the Toxicological Profiles.
 
Developmental Toxicity -- The occurrence of adverse effects on the developing
 
organism that may result from exposure to a chemical prior to conception
 
(either parent), during prenatal development, or postnatally to the time of
 
sexual maturation. Adverse developmental effects may be detected at any point
 
in the life span of the organism.
 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a
 
result of prenatal exposure to a chemical; the distinguishing feature between
 
the two terms is the stage of development during which the insult occurred.
 
The terms, as used here, include malformations and variations, altered growth,
 
and in utero death.
 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a
 
chemical substance based on health effects information. A health advisory is
 
not a legally enforceable federal standard, but serves as technical guidance to
 
assist federal, state, and local officials.
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Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental 
concentration of a contaminant from which one could escape within 30 min 
without any escape-impairing symptoms or irreversible health effects. 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days
 
as specified in the Toxicological Profiles.
 
Immunologic Toxicity -- The occurrence of adverse effects on the immune system
 
that may result from exposure to environmental agents such as chemicals.
 
In Vitro -- Isolated from the living organism and artificially maintained, as
 
in a test tube.
 
In Vivo -- Occurring within the living organism.
 
Lethal Concentration(Lo)(LCLo) -- The lowest concentration of a chemical in air 
which has been reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50) -- A calculated concentration of a chemical in 
air to which exposure for a specific length of time is expected to cause death 
in 50% of a defined experimental animal population. 
Lethal Dose(Loj (LDLo) -- The lowest dose of a chemical introduced by a route
 
other than inhalation that is expected to have caused death in humans or
 
animals.
 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated to 
cause death in 50% of a defined experimental animal population. 
Lethal Time(50) (LT50) -- A calculated period of time within which a specific
 
concentration of a chemical is expected to cause death in 50% of a defined
 
experimental animal population.
 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in
 
a study or group of studies, that produces statistically or biologically
 
significant increases in frequency or severity of adverse effects between the
 
exposed population and its appropriate control.
 
Malformations -- Permanent structural changes that may adversely affect
 
survival, development, or function.
 
Minimal Risk Level -- An estimate of daily human exposure to a chemical that is
 
likely to be without an appreciable risk of deleterious effects
 
(noncancerous) over a specified duration of exposure.
 
Mutagen -- A substance that causes mutations. A mutation is a change in the
 
genetic material in a body cell. Mutations can lead to birth defects,
 
miscarriages, or cancer.
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Neurotoxicity -- The occurrence of adverse effects on the nervous system
 
following exposure to chemical.
 
No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which there
 
were no statistically or biologically significant increases in frequency or
 
severity of adverse effects seen between the exposed population and its
 
appropriate control. Effects may be produced at this dose, but they are not
 
considered to be adverse.
 
Octanol-Water Partition Coefficient (Kow) -- The equilibrium ratio of the 
concentrations of a chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace 
air averaged over an 8-hour shift. 
q1* -- The upper-bound estimate of the low-dose slope of the dose-response
 
curve -as determined by the multistage procedure. The ql* can be used to
 
calculate an estimate of carcinogenic potency, the incremental excess cancer
 
risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an
 
order of magnitude) of the daily exposure of the human population to a
 
potential hazard that is likely to be without risk of deleterious effects
 
during a lifetime. The RfD is operationally derived from the NOAEL (from
 
animal and human studies) by a consistent application of uncertainty factors
 
that reflect various types of data used to estimate RfDs and an additional
 
modifying factor, which is based on a professional judgment of the entire
 
database on the chemical. The RfDs are not applicable to nonthreshold effects
 
such as cancer.
 
Reportable Quantity (RQ) -- The quantity of'a hazardous substance that is
 
considered reportable under CERCLA. Reportable quantities are: (1) 1 lb or
 
greater or (2) for selected substances, an amount established by regulation
 
either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are
 
measured over a 24-hour period.
 
Reproductive Toxicity -- The occurrence of adverse effects on the reproductive
 
system that may result from exposure to a chemical. The toxicity may be
 
directed to the reproductive organs and/or the related endocrine system. The
 
manifestation of such toxicity may be noted as alterations in sexual behavior,
 
fertility, pregnancy outcomes, or modifications in other functions that are
 
dependent on the integrity of this system.
 
Short-Term Exposure Limit (STEL) -- The maximum concentration to which workers
 
can be exposed for up to 15 min continually. No more than four excursions are
 
allowed per day, and there must be at least 60 min between exposure periods.
 
The daily TLV-TWA may not be exceeded.
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9. GLOSSARY
 
Target Organ Toxicity -- This term covers a broad range of adverse effects on
 
target organs or physiological systems (e.g., renal, cardiovascular) extending
 
from those arising through a single limited exposure to those assumed over a
 
lifetime of exposure to a chemical. 
Teratogen -- A chemical that causes structural defects that affect the
 
development of an organism.
 
Threshold Limit Value (TLV) -- A concentration of a substance to which most
 
workers can be exposed without adverse effect. The TLV may be expressed as a
 
TWA, as a STEL, or as a CL.
 
Time-weighted Average (TWA) -- An allowable exposure concentration averaged
 
over a normal 8-hour workday or 40-hour workweek.
 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route 
other than inhalation, which is expected to cause a specific toxic effect in 
50% of a defined experimental animal population. 
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD
 
from experimental data. UFs are intended to account for (1) the variation in
 
sensitivity among the members of the human population, (2) the uncertainty in
 
extrapolating animal data to the case of human, (3) the uncertainty in
 
extrapolating from data obtained in a study that is of less than lifetime
 
exposure, and (4) the uncertainty in using LOAEL data rather than NOAEL data.
 
Usually each of these factors is set equal to 10.
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USER'S GUIDE
 
Chapter 1
 
Public Health Statement
 
This chapter of the profile is a health effects summary written in nontechnical
 
language. Its intended audience is the general public especially people living
 
in the vicinity of a hazardous waste site or substance release. If the Public
 
Health Statement were removed from the rest of the document, it would still
 
communicate to the lay public essential information about the substance.
 
The major headings in the Public Health Statement are useful to find specific
 
topics of concern. The topics are written in a question and answer format. The
 
answer to each question includes a sentence that will direct the reader to
 
chapters in the profile that will provide more information on the given topic.
 
Chapter 2
 
Tables and Figures for Levels of Significant Exposure (LSE)
 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize
 
health effects by duration of exposure and endpoint and to illustrate
 
graphically levels of exposure associated with those effects. All entries in
 
these tables andfigures represent studies that provide reliable, quantitative
 
estimates of No-Observed-Adverse-Effect Levels (NOAELS), Lowest-Observed­
Adverse-Effect Levels (LOAELs) for Less Serious and Serious health effects, or
 
Cancer Effect Levels (CELs). In addition, these tables and figures illustrate
 
differences in response by species, Minimal Risk Levels (MRLs) to humans for
 
noncancer end points, and EPA'S estimated range associated with an upper-bound
 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE
 
tables and figures can be used for a quick review of the health effects and to
 
locate data for a specific exposure scenario. The LSE tables and figures should
 
always be used in conjunction with the text.
 
The legends presented below demonstrate the application of these tables and
 
figures. A representative example of LSE Table 2-l and Figure 2-1 are shown.
 
The numbers in the left column of the legends correspond to the numbers in the
 
example table and figure.
 
LEGEND
 
See LSE Table 2-1
 
(1) Route of Exposure One of the first considerations when reviewing the

 toxicity of a substance using these tables and figures should be the

 relevant and appropriate route of exposure. When sufficient data exist,
 
  
A-2
 
APPENDIX A
 
three LSE tables and two LSE figures are presented in the document. The
 
three LSE tables present data on the three principal routes of exposure,
 
i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3,
 
respectively). LSE figures are limited to the inhalation (LSE Figure 2­
l)and oral (LSE Figure 2-2) routes.
 
(2)	 Exposure Duration Three exposure periods: acute (14 days or less);
 
intermediate (15 to 364 days); and chronic (365 days or more) are
 
presented within each route of exposure. In this example, an inhalation
 
study of intermediate duration exposure is reported.
 
(3)	 Health Effect The major categories of health effects included in
 
LSE tables and figures are death, systemic, immunological,
 
neurological, developmental, reproductive, and cancer. NOAELs and
 
LOAELs can be reported in the tables and figures for all effects but
 
cancer. Systemic effects are further defined in the "System" column
 
of the LSE table.
 
(4)	 Kev to Figure Each key number in the LSE table links study information to
 
one or more data points using the same key number in the corresponding
 
LSE figure. In this example, the study represented by key number 18 has
 
been used to define a NOAEL and a Less Serious LOAEL (also see the two
 
"18r" data points in Figure 2-l).
 
(5)	 Species The test species, whether animal or human, are identified in this
 
column.
 
(6)	 Exposure Frequencv/Duration The duration of the study and the weekly and
 
daily exposure regimen are provided in this column. This permits
 
comparison of NOAELs and LOAELs from different studies. In this case (key
 
number 18), rats were exposed to [substance x] via inhalation for 13
 
weeks, 5 days per week, for 6 hours per day.
 
(7) 	 System This column further defines the systemic effects. These systems
 
include: respiratory, cardiovascular, gastrointestinal, hematological,
 
musculoskeletal, hepatic, renal, anddermal/ocular. "Other" refers to any
 
systemic effect (e.g., a decrease in body weight) not covered in these
 
systems. In the example of key number 18, one systemic effect
 
respiratory) was investigated in this study.
 
(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure
 
level at which no harmful effects were seen in the organ system studied.
 
Key number 18 reports a NOAEL of 3 ppm for the respiratory system which
 
was used to derive an intermediate exposure, inhalation MRL of 0.00s ppm
 
(see footnote "c").
 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest
 
exposure level used in the study that caused a harmful health effect.
 
LOAELs have been classified into "Less Serious" and "Serious" effects.
 
These distinctions help readers identify the levels of exposure at which
 
adverse health effects first appear and the gradation of effects with
 
increasing dose. A brief description of the specific end point used to
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quantify the adverse effect accompanies the LOAEL. The "Less Serious"
 
respiratory effect reported in key number 18 (hyperplasia) occurred at a
 
LOAEL of 10 ppm.
 
(10)	 Reference The complete reference citation is given in Chapter 8 of the
 
profile.
 
(11)	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated
 
with the onset of carcinogenesis in experimental or epidemiological
 
studies. CELs are always considered serious effects. The LSE tables and
 
figures do not contain NOAELs for cancer, but the text may report doses
 
which did not cause a measurable increase in cancer.
 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in
 
the LSE tables are found in the footnotes. Footnote "c" indicates the
 
NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.
 
LEGEND
 
See LSE Figure 2-l
 
LSE figures graphically illustrate the data presented in the corresponding LSE
 
tables. Figures help the reader quickly compare health effects according to
 
exposure levels for particular exposure duration.
 
(13)	 Exposure Duration The same exposure periods appear as in the LSE table.
 
In this example, health effects observed within the intermediate and
 
chronic exposure periods are illustrated.
 
(14)	 Health Effects These are the categories of health effects for which
 
reliable quantitative data exist. The same health effects appear in the
 
LSE table.
 
(15)	 Levels of Exposure Exposure levels for each health effect in the LSE
 
tables are graphically displayed in the LSE figures. Exposure levels are
 
reported on the log scale "y" axis. Inhalation exposure is reported in
 
mg/m3 or ppm and oral exposure is reported in mg/kg/day.
 
(16)	 NOAEL In this example, 18r NOAEL is the critical end point for which an
 
intermediate inhalation exposure MRL is based. As you can see from the
 
LSE figure key, the open-circle symbol indicates a NOAEL for the test
 
species (rat). The key number 18 corresponds to the entry in the LSE
 
table. The dashed descending arrow indicates the extrapolation from the
 
exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005
 
ppm (see footnote "b" in the LSE table).
 
(17)	 CEL Key number 38r is one of three studies for which Cancer Effect Levels
 
(CELs) were derived. The diamond symbol refers to a CEL for the test
 
species (rat). The number 38 corresponds to the entry in the LSE table.
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(18). Estimated Upper-Bound Human Cancer Risk Levels This is the range
 
associated with the upper-bound for lifetime cancer risk of 1 in 10,000
 
to 1 in 10,000,000. These risk levels are derived from EPA's Human Health
 
Assessment Group's upper-bound estimates of the slope of the cancer dose
 
response curve at low dose levels (q1*).
 
(19). Key to LSE Figure The Key explains the abbreviations and symbols used in
 
the figure.
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Chapter 2 (Section 2.4)
 
Relevance to Public Health
 
The Relevance to Public Health section provides a health effects summary based
 
on evaluations of existing toxicological, epidemiological, and toxicokinetic
 
information. This summary is designed to present interpretive,
 
weight-of-evidence discussions for human health end points by addressing the
 
following questions.
 
1. What effects are known to occur in humans?
 
2. What effects observed in animals are likely to be of concern to
 
humans?
 
3. What exposure conditions are likely to be of concern to humans,
 
especially around hazardous waste sites?
 
The section discusses health effects by end point. Human data are presented
 
first, then animal data. Both are organized by route of exposure (inhalation,
 
oral, and dermal) and by duration (acute, intermediate, and chronic). In vitro
 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous,
 
etc.) are also considered in this section. If data are located in the
 
scientific literature, a table of genotoxicity information is included.
 
The carcinogenic potential of the profiled substance is qualitatively
 
evaluated, when appropriate, using existing toxicokinetic, genotoxic, and
 
carcinogenic data. ATSDR does not currently assess cancer potency or perform
 
cancer risk assessments. MRLs for noncancer end points if derived, and the end
 
points from which they were derived are indicated and discussed in the
 
appropriate section(s).
 
Limitations to existing scientific literature that prevent a satisfactory
 
evaluation of the relevance to public health are identified in the
 
Identification of Data Needs section.
 
Interpretation of Minimal Risk Levels
 
Where sufficient toxicologic information was available, MRLs were derived. MRLs
 
are specific for route (inhalation or oral) and duration (acute, intermediate,
 
or chronic) of exposure. Ideally, MRLs can be derived from all six exposure
 
scenarios (e.g., Inhalation - acute, -intermediate, -chronic; Oral - acute, ­
intermediate, - chronic). These MRLs are not meant to support regulatory
 
action, but to acquaint health professionals with exposure levels at which
 
adverse health effects are not expected to occur in humans. They should help
 
physicians and public health officials determine the safety of a community
 
living near a substance emission, given the concentration of a contaminant in
 
air or the estimated daily dose received via food or water. MRLs are based
 
largely on toxicological studies in animals and on reports of human
 
occupational exposure.
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MRL users should be familiar with the toxicological information on which the
 
number is based. Section 2.4, "Relevance to Public Health," contains basic
 
informationknown about the substance. Other sections such as 2.6, "Interactions
 
with Other Chemicals" and 2.7, "Populations that are Unusually Susceptible"
 
provide important supplemental information.
 
MRL users should also understand the MRL derivation methodology. MRLs are
 
derived using a modified version of the risk assessment methodology used by the
 
Environmental Protection Agency (EPA) (Barnes and Dourson, 1988; EPA 1989a) to
 
derive reference doses (RfDs) for lifetime exposure.
 
To derive an MRL, ATSDR generally selects the end point which, in its best
 
judgement, represents the most sensitive humanhealth effect for a given
 
exposure route and duration. ATSDR cannot make this judgement or derive an MRL
 
unless information (quantitative or qualitative) is available for all potential
 
effects (e.g., systemic, neurological, and developmental). In order to compare
 
NOAELs and LOAELs for specific end points, all inhalation exposure levels are
 
adjusted for 24hr exposures and all intermittent exposures for inhalation and
 
oral routes of intermediate and chronic duration are adjusted for continous
 
exposure (i.e., 7 days/week). If the information and reliable quantitative data
 
on the chosen end point are available, ATSDR derives an MRL using the most
 
sensitive species (when information from multiple species is available) with
 
the highest NOAEL that does not exceed any adverse effect levels. The NOAEL is
 
the most suitable end point for deriving an MRL. When a NOAEL is not available,
 
a Less Serious LOAEL can be used to derive an MRL, and an uncertainty factor
 
(UF) of 10 is employed. MRLs are not derived from Serious LOAELs. Additional
 
uncertainty factors of 10 each are used for human variability to protect
 
sensitive subpopulations (people who are most susceptible to the health effects
 
caused by the substance) and for interspecies variability (extrapolation from
 
animals to humans). In deriving an MRL, these individual uncertainty factors
 
are multiplied together. The product is then divided into the adjusted
 
inhalation concentration or oral dosage selected from the study. Uncertainty
 
factors used in developing a substance-specific MRL are provided in the
 
footnotes of the LSE Tables.
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PEER REVIEW
 
A peer review panel was assembled for methyl mercaptan. The panel
 
consisted of the following members: Dr. Sharon Johnson, Visiting Scientist,
 
Department of Biology, Johns Hopkins University; Dr. Derek Hodgson, Chairman,
 
Department of Chemistry, University of Wyoming; Dr. Shane Que Hee, Associate
 
Professor, School of Public Health, University of California. These experts
 
collectively have knowledge of methyl mercaptan's physical and chemical
 
properties, toxicokinetics, key health end points, mechanisms of action, human
 
and animal exposure, and quantification of risk to humans. All reviewers were
 
selected in conformity with the conditions for peer review specified in Section
 
104(i)(13) of the Comprehensive Environmental Response, Compensation, and
 
Liability, as amended.
 
A joint panel of scientists from the Agency for Toxic Substances and
 
Disease Registry (ATSDR) and the Environmental Protection Agency has reviewed
 
the peer reviewers' comments and determined which comments will be included in
 
the profile. A listing of the peer reviewers' comments not incorporated in
 
the profile, with a brief explanation of the rationale for their exclusion,
 
exists as part of the administrative record for this compound. A list of
 
databases reviewed and a list of unpublished documents cited are also included
 
in the administrative record.
 
The citation of the peer review panel should not be understood to imply
 
its approval of the profile's final content. The responsibility for the
 
content of this profile lies with the ATSDR.
 
